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ABSTRACT 
 
 This dissertation studies the regulatory mechanism of IL-2 inducible tyrosine 
kinase (ITK) and its substrate phospholipase C γ1 (PLCγ1).  ITK and PLCγ1 are key 
mediators of the signaling pathway downstream of the T cell receptor that results in the T 
cell part of the adaptive immune response. In T cells, ITK is phosphorylated and 
activated by LCK. ITK then phosphorylates PLCγ1 at tyrosine 783 and activates 
phospholipase activity. This phosphorylation is dependent upon various coordinated 
intermolecular and intramolecular interactions within and between ITK and PLCγ1. This 
dissertation identifies and characterizes various regulatory interactions in ITK and its 
substrate PLCγ1 that regulates ITK mediated phosphorylation of PLCγ1.  
 
For ITK, this thesis explores the function of the N-terminal Pleckstrin homology 
(PH) domain in regulating the activation of the ITK. The ITK PH domain engages in 
direct interaction with ITK kinase domain and the region of the kinase domain interaction 
is mapped in the ITK PH domain. Mutations in ITK PH domain, that disrupts its 
interaction with kinase domain, lead to the increase in the activity of ITK. The ITK 
interaction surface mapped on the ITK PH domain lies adjacent to its 
phosphatidylinositol (3,4,5)-triphosphate (PI (3,4,5) P3) binding pocket. Hence, IP4, the 
soluble head group of (PI (3,4,5) P3) competes with the ITK kinase domain for ITK PH 
domain binding. Also, PI (3,4,5) P3 binding of ITK PH domain increases the catalytic 
activity of the ITK. In addition, PI (3,4,5) P3 binding increases the activation loop Y511 
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accessibility for LCK phosphorylation. This study expanded our knowledge on regulation 
of ITK by its N terminal PH domain (Chapter 3).  
 
ITK is a key modulator of immune response and has therefore been very attractive 
target for small molecule intervention for immunity related diseases such as autoimmune 
disease and asthma. The key novel regulatory ITK PH/kinase site can be a plausible 
allosteric target for small molecule discovery efforts. Part of this thesis contributes to 
assay development to detect the ITK PH/Kinase interaction in cells. Bimolecular 
Fluorescence complementation (BiFC) assay confirms that the ITK PH/Kinase 
interaction occurs in cell (Chapter 4). This assay can now be used to screen for small 
molecules that modulate the ITK PH/Kinase interaction.  
 
For PLCγ1, this thesis studies the mechanism of disruption of its autoinhibitory 
conformation. The PLCγ1 autoinhibitory conformation is characterized by an 
intramolecular interaction between the C terminal SRC homology 2 (SH2C) domain and 
the adjacent linker containing Y783. This conformation makes the crucial 
phosphorylation target (Y783) inaccessible to ITK. I have described the mechanism on 
how this autoinhibitory interaction is broken (Chapter 2). Our results suggest that the 
scaffold protein SLP-76 disrupts the autoinhibitory PLCγ1 conformation. More 
specifically, SLP-76 phosphotyrosine 173 (Y173) binds the SH2C domain of the PLCγ1, 
competing with the autoinhibitory conformation of PLCγ1 and releasing the linker, 
making the Y783 more accessible to ITK. Our results identify the new role of the scaffold 
protein SLP-76 adding to its previously described role in co-localizing the enzyme and 
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substrate pair. This role is defined as the substrate priming as SLP-76 primes PLCγ1, the 
substrate for ITK for efficient phosphorylation. Our results provide further understanding 
of the regulation of ITK mediated phosphorylation of PLCγ1 and create a foundation for 
small molecule discovery efforts that should yield new ways to either enhance or 
diminish T cell function. 
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CHAPTER 1 
 GENERAL INTRODUCTION  
 
Signal transduction in cells is mediated by protein phosphorylation, carried out by 
enzymes known as kinases. Protein kinases specifically transfer the γ-phosphate from 
adenosine triphosphate (ATP) to hydroxyl containing side chains of the substrate protein. 
Tyrosine kinases are responsible for phosphorylating tyrosine residues on their substrates 
and are divided into two categories, receptor tyrosine kinases and non-receptor tyrosine 
kinases. Kinases play crucial roles in various cellular processes like signal transduction, 
cell cycle, metabolism and apoptosis (1, 2). Links between abnormal regulation of protein 
phosphorylation and diseases have been found, and hence highlight the need to study the 
complex mechanism of regulation of kinases and their substrates (3, 4).  
  
Our lab studies non-receptor tyrosine kinases belonging to TEC family, more 
specifically, two homologs, Interleukin-2 inducible tyrosine kinase (ITK) and Bruton’s 
tyrosine kinase (BTK), which are primarily expressed and mediate signal transduction in 
T-cells and B-cells, respectively (5). ITK and BTK phosphorylate the substrate 
Phospholipase C γ1 (PLCγ1) and Phospholipase C γ2 (PLCγ2) respectively, and activate 
these lipases. Proper regulation of both ITK and BTK is crucial for normal signal 
transduction within these immune cells. Deregulation of these kinases causes a failure in 
T and B cells to develop normally, resulting in compromised immunity, making 
individuals vulnerable to severe infections (3). Mutations in Btk are the cause of X-linked 
agammaglobulinemia (XLA), a disease characterized by failure to develop appropriate 
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immune responses (6). These mutations, causes loss of BTK activity resulting in 
significant decrease mature B cells in blood and reduced immunoglobulins, leading to a 
severely compromised immune response. Similarly, loss of function mutations in ITK 
leads to fatal Epstein-Barr virus induced lymphoproliferative diseases (EBV-LPD) (7). 
As well, ITK has also been shown to play a role in HIV infectivity and replication (3, 8, 
9). In addition, ITK has been linked to autoimmune diseases like multiple sclerosis and 
inflammatory bowel diseases (10). The connections between ITK and various 
immunological diseases make ITK an attractive drug target. However, better 
understanding of the specific molecular regulatory mechanisms that control ITK enzyme 
activity is essential. Hence this dissertation deciphers the regulatory mechanisms of ITK 
and its substrate PLCγ1 that govern the activity of the ITK.   
 
ITK and PLCγ1 are both modular proteins regulated by complex intramolecular 
interactions within their domains. In addition, PLCγ1 phosphorylation takes place in the 
context of larger signalosome complex formed by the scaffold proteins SRC homology 2 
domain containing leucocyte protein of 76 kDa (SLP-76), linker of activation of T cells 
(LAT) and GRB2-related adapter protein (GADS) (11). This dissertation investigates the 
intermolecular interactions between ITK, PLCγ1 and the adaptor protein SLP-76 that is 
necessary for selective phosphorylation of PLCγ1 by ITK. In addition, it also investigates 
the autoregulation mechanism of ITK. We have identified a specific intramolecular 
interaction within ITK that maintains ITK in its autoinhibited state. Also, this dissertation 
describes the mechanism of transition from the ITK autoinhibited state to the ITK 
activated state required for proper T cell signaling. 
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Literature Review 
1.  ITK, PLCγ1 and SLP-76 in the T cell signaling pathway 
ITK, PLCγ1 and SLP-76 are involved in signal transduction downstream of the T-
cell receptor (TCR). The T cell receptor is activated when antigen bound by the Major 
Histocompatibility Complex I (MHC I) is engaged by the TCR (12). This process is also 
called TCR ligation. TCR ligation is followed by rapid activation of LCK and ZAP-70 
tyrosine kinases. These kinases then phosphorylate different molecules. LCK 
phosphorylates and activates phosphoinositide 3-kinase, which in turn phosphorylates 
phosphatidylinositol (4,5)-diphosphate making phosphatidylinositol (3,4,5)-triphosphate 
(13). Zap-70 phosphorylates the scaffold proteins LAT and SLP-76. These 
phosphorylated scaffold proteins lack intrinsic catalytic activity but form the backbone of 
the TCR signaling complex, as they serve as a platform for the assembly of other 
molecules into the signaling complex. Both ITK and its substrate PLC γ1 are co-localized 
in the signaling complex by binding to LAT and SLP-76. ITK also gets targeted into the 
membrane via the interaction between its PH domain and phosphatidylinositiol (3,4,5)-
triphosphate (13). Within this complex ITK is phosphorylated by LCK leading to ITK 
activation. Other molecules that are part of this signaling complex are GRB2, GADS, 
ADAP, VAV and NCK (12, 14). This signaling complex imparts signals into three major 
pathways, leading to gene expression, actin reorganization and cell adhesion (14-16).  
 
Gene expression is mediated by ITK when it phosphorylates PLCγ1 at tyrosine 
783 (Y783), which leads to PLCγ1 activation (17). Activated PLCγ1 hydrolyzes the 
membrane lipid phosphatidylinositol-4, 5-bisphosphate (PIP2) producing two key second 
 4 
messengers, inositol-1, 4, 5-triphosphate (IP3) and diacylglycerol (DAG). IP3 binds to 
receptors on the endoplasmic reticulum and trigger the release of intracellular Ca2+ ions, 
which then stimulates Ca2+ release activated Ca2+ channels (CRAC) leading to influx of 
extracellular Ca2+ (18-20). The calcium binding protein Calmodulin binds with Ca2+ ions 
and activates the phosphatase Calcineurin, which dephosphorylates the transcription 
factor NFAT, inducing the translocation of transcription factor NFAT into the nucleus 
(21). Calcium bound calmodulin also binds ITK, enhancing the recruitment of ITK to the 
membrane. DAG on the other hand plays a role in the activation of both PKC and 
MAPK/Erk pathways, which promotes transcription factors NFκB (22). These 
transcription factors regulate the expression of various cytokines like IL-2 for appropriate 
immune response. 
 
 
 
 
Figure 1. ITK, its substrate PLCγ1 and adaptor protein SLP-76 in TCR signaling 
pathway. ITK phosphorylates PLCγ1 within of signaling complex formed by scaffold 
proteins including SLP-76, ultimately leading this pathway for gene expression. 
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2. ITK 
ITK is a member of TEC family of non- receptor tyrosine kinase along with BTK, 
BMX, TEC and TXK. TEC family kinases are expressed in hematopoietic cells and 
regulate the development, activation and differentiation of lymphocytes (17). ITK is a 72-
kDa protein, primarily expressed in T cells and, as already described, is a key mediator of 
the T cell signaling pathway. The domain structure of ITK along with other TEC family 
kinases, with the exception of TXK, is unique among non-receptor tyrosine kinases 
because of the presence of the amino terminal Pleckstrin homology (PH domain) (23). 
The PH domain is followed by Zn2+ binding Tec Homology (TH) motif, a proline rich 
region (PRR), Src homology 3 (SH3) domain, Src homology 2 (SH2) domain and kinase 
domain. The domain organization is illustrated in Figure 2. The function of the PH 
domain is to bind Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) in the membrane, 
hence co-localizing ITK with other proteins in the signaling complex. The SH3 domain is 
known to bind proline-rich sequences and the SH2 domain recognizes and binds 
phosphotyrosine containing motifs. The kinase domain is the catalytic domain, which 
carries out the transfer of the γ-phosphate from ATP to tyrosine residues of the substrates. 
Like all other kinase domain, the ITK kinase domain is a bilobal structure with a smaller 
N lobe and a larger C lobe. The N lobe consist of five beta strands and one critical α 
helix called αC helix. The C lobe is composed of mainly α helices. The active site where 
phosphate transfer occurs is formed within the cleft between the N lobe and C lobe.  
 
 
Figure 2. Domain organization of ITK 
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3. PLCγ1 
PLCγ1 is a phospholipase, which catalyzes the hydrolysis of PIP2 to IP3 and 
DAG. In T cells, PLCγ1 is the key substrate of ITK. ITK phosphorylates PLCγ1 and 
activates its lipase activity. PLCγ1 is among 13 mammalian isozymes, which are divided 
into six groups: PLCβ, PLCγ, PLCδ, PLCε, PLCζ, and PLCη (24). PLC enzymes are key 
enzymes in signal transduction pathways, linking various cell receptors and downstream 
effectors proteins that are involved in regulation of various cellular processes. PLCγ 
isozymes (γ1 and γ2) are activated through phosphorylation mediated by receptor and 
non-receptor tyrosine kinases. PLCγ1 is expressed ubiquitously and is involved in 
signaling pathway downstream of receptors like platelet-derived growth factor (PDGF), 
fibroblast growth factor (FGF), epidermal growth factor (EGF), nerve growth factor 
(NGF) and T cell receptor, while PLCγ2 is expressed in B cells and is involved in signal 
transmission downstream of B cell receptor (25).  
 
PLCγ1 and PLCγ2 both have the same domain arrangement, which consist of a 
core set of domains (PLC-core) and an array of regulatory modules called γ-specific array 
(γ-SA) unique to PLCγ isozymes. PLC core consists of N terminal Pleckstrin homology 
(PH) domain, EF-hands, catalytic triosephosphate isomerase (TIM) barrel fold and a C2 
domain. The two halves (X and Y boxes) of the TIM barrel is separated by γ-SA. The γ-
SA consists of a split PH domain, two Src homology domains (SH2N and SH2C for N 
and C terminal respectively) and an Src homology 3 (SH3) domain. The domain 
organization of PLCγ1 is shown in Figure 3. 
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Figure 3.   Domain organization of PLCγ1 
 
4. SH2 domains and its role in regulating PLCγ1 
 The SH2 domain is present in molecules involved in signaling and mediates 
protein-protein interactions by binding to a phosphotyrosine ligand. All SH2 domains 
have a conserved three-dimensional structure with a central beta sheet flanked by a helix 
on each side (26). The SH2-pY mode of binding is shown in figure 4. The conserved 
arginine in the pY pocket of the SH2 domain interacts with the phosphotyrosine ligand 
phosphate (26). The hydrophobic pocket also known as pY+3 pocket, accommodates 
mostly hydrophobic residue (pY+3) in the peptide ligand.  
Figure 4. The structure of PLCγ1 SH2 domain adapted from reference number (27). The 
phosphotyrosine ligand is shown in red. PDB ID: 2PLD  
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SH2 domains of the PLCγ1 plays important role in its regulation. PLCγ1 has two 
SH2 domains SH2N and SH2C. Both SH2 domains are the part of γ-SA region and this γ-
SA region of the PLCγ1 helps regulate the enzymatic activity. Deletion of the γ-SA 
regions leads to 20- to 100- fold increase in PLCγ1 activity (28). However, lack of high-
resolution structural data for full-length PLCγ1, makes it difficult to study the precise 
mechanism on how the γ-SA region regulates PLCγ1 activation. However, lower 
resolution small angle light scattering data and NMR titration experiments pinpoint the 
role of SH2C domain that inhibits lipase activity. SH2C domain involve in binding PLC 
core containing split catalytic domain maintaining PLCγ1 in inactivated state (29). ITK 
phosphorylation of PLCγ1 is required to release the inactivated state. 
 
SH2C not only regulates PLCγ1 lipase activity by directly interacting with the 
PLC core, it also regulates PLCγ1 phosphorylation by ITK. The phosphorylation target 
tyrosine 783 (Y783) is within the 33 amino acid long linker placed between SH2C 
domain and SH3 domain (Figure 3). Studies from our laboratory have also shown that 
PLCγ1 SH2C and ITK kinase domain directly interact (30). The interaction surface on 
both ITK kinase domain and PLCγ1 C terminal SH2 domain have been mapped and are 
shown as red residues in Figure 5. In ITK kinase domain, interaction is mediated by G 
helix in the C lobe while in SH2 domain various loop residues are critical for the 
interaction. This interaction is also defined as a substrate docking interaction, since it 
confers specificity and selectivity of the substrate. This specific interaction facilitates 
efficient phosphorylation of tyrosine 783 located in the long linker adjacent to the SH2 
domain in PLCγ1 (30-32). The importance of this interaction is underscored by the fact 
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mutation that disrupts the docking interaction surface results in diminished Ca2+ in Jurkat 
T cells (31).   
 
 
 
Figure 5. Structures of ITK kinase domain (PDB:1SNU) and PLCγ1 SH2C (PDB: 2PLD) 
domain with residues shown in red, that are involved in substrate docking interaction. 
 
After ITK phosphorylation of PLCγ1 at Y783, phosphorylated linker undergoes 
intramolecular interactions with its SH2C domain. The crystal structure of the SH2N-
SH2C-linker fragment reveals that PLCγ1 Y783, when phosphorylated, interacts with the 
SH2C domain in canonical fashion, where pY783 is accommodated in pY pocket and 
pY+3 residue is accommodated in pY+3 pocket. (Figure 6a). This intramolecular 
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interaction of SH2C domain and phosphorylated linker disrupts the SH2C domain 
interaction with the PLC core hence releases PLCγ1 inactivated state described above.  
  
However, another crystal structure of the PLCγ1 SH2N-SH2C-linker fragment 
reveals that the SH2-linker interacts with the SH2 domain even when PLCγ1 Y783 is not 
phosphorylated (Figure 6b) (29). The linker conformation for unphosphorylated form is 
very similar to phosphorylated form except for the tyrosine 783 is pointed outward and 
does not occupy the pY pocket in SH2C (Figure 5b). This conformation of the PLCγ1 is 
thought to be autoinhibitory in nature because the Y783 is inaccessible to ITK for 
phosphorylation. This autoinhibitory interaction adds another regulatory layer, where 
Y783 cannot be phosphorylated, unless this interaction is disrupted. However, 
confirmation of this intramolecular interaction is necessary because artifact from crystal 
packing could also lead to this conformation.  
 
So we asked, whether this interaction is real and takes place in solution and if so, 
whether this makes Y783 in linker inaccessible to ITK and how this interaction is 
disrupted so that ITK can readily phosphorylate the Y783. Chapter 2 of this thesis 
precisely addresses these questions. We explore the possible role of scaffold protein SLP-
76, on disrupting the autoinhibitory PLCγ1 interaction in chapter 2.  
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Figure 6. Crystal structure of SH2N-SH2C-linker, phosphorylated form (a) (PDB:4FBN) 
and unphosphorylated form (b) (PDB:4EY0). The linker with ITK phosphorylation site is 
shown in red. Missing part of linker is shown as dashed line.   
 
5. SLP-76 
SLP-76 is a scaffold protein, mostly expressed in hematopoietic cell types. It 
consists of three modular domains: N terminal acidic region with four phosphotyrosine 
motifs, central proline rich domain and a C-terminal SH2 domain (33) ( Figure 6). These 
domains with their distinct ligand binding properties help regulate the assembly and 
localization of different proteins to form signaling complexes. SLP-76 on its N terminal 
acidic domain contains three tyrosine phosphorylation sites (Y113, Y128, Y145) that are 
known to be phosphorylated by ZAP-70 (34). These phosphorylated tyrosine mediate 
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interactions with the guanine nucleotide exchange factor VAV, the adapter NCK, and 
ITK (35, 36). ITK has been shown to bind to pY145 of SLP-76 (36). Binding of ITK SH2 
to SLP-76 pY145 helps localize ITK to a larger signaling complex resulting in the 
phosphorylation and activation of its substrate.  
 
Recently, a new phosphorylation site (Y173) has been discovered in SLP-76 and 
this specific tyrosine unlike the other phosphorylation sites on SLP-76 is phosphorylated 
by ITK and not by ZAP-70 (34). Mutation of Y173F in SLP-76 leads to abrogation of 
phosphorylation of PLCγ1 at Y783 (34). However, the detail mechanism on how Y173 is 
involved in phosphorylation of PLCγ1 Y783 is not known. In chapter 2, we describe the 
how pY173 is involved in disrupting PLCγ1 autoinhibitory conformation (described 
above) leading to the efficient phosphorylation of Y783 by ITK. 
 
 
 
 
Figure 6. Domain organization of SLP-76 
 
6. ITK regulation 
Multiple layers of molecular mechanisms regulate activation of ITK. After T cell 
activation, ITK is localized to membrane via its PH domain binding PI(3,4,5)P3. 
Phosphorylation at a specific residue within the activation loop is required for the 
activation of most kinases including those of the TEC family. ITK is phosphorylated on 
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the activation loop tyrosine (Y511) in the kinase domain by the SRC family kinase LCK 
(37). Phosphorylation on the ITK activation loop enhances the catalytic activity of the 
ITK (37). Phosphorylation in the activation loop causes conformational changes within 
kinase domain that allow for catalysis to occur. More specifically, after activation loop 
phosphorylation, the activation loop moves out of the active site allowing for the αC 
helix containing a conserved glutamate residue to swing in towards the active site and 
form a crucial salt bridge between the αC helix glutamate side chain and a conserved 
lysine side chain in the N lobe.  
 
Following T cell activation, ITK also associates with signaling complex formed 
by adaptor proteins LAT and SLP-76 localizing ITK with its substrate PLCγ1. 
Specifically, ITK SH2 and SH3 domain binds the scaffold protein SLP-76 
phosphotyrosine 145 and proline rich region respectively. Within this signaling complex 
ITK, associates with its substrate PLCγ1 by substrate docking mechanism as described 
above and phosphorylates it.  
 
These intermolecular interactions, likely rearrange the tertiary structure of the 
ITK leading to its activation. Previous studies have shown that the rearrangement of the 
tertiary structure of the protein controls the activation status of the kinases (38, 39). For 
example crystal structures of SRC kinases in the inactive conformation shows that the 
SH2 domain binds to a conserved C-terminal regulatory phosphotyrosine on the Kinase 
tail (40). TEC family kinases, however are likely to be regulated differently because they 
lack the conserved tyrosine in the C terminal kinase tail but instead contain N terminal 
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PHTH domain which is absent in SRC family kinases. Full-length crystal structures of 
the TEC kinases are currently unavailable. However, a recent crystal structure of Tec 
family member kinase BTK reveals intramolecular interactions in autoinhibited state of 
the protein. In BTK, the crystal structure of the SH2-SH3-Kinase fragment reveals the 
intramolecular interaction between domains and mutation in interaction interface causes 
increase in the catalytic activity of BTK (41). However, ITK full-length structure is not 
available, but deletion mutation studies suggest the inhibitory role of SH3, SH2 and 
PHTH domain on catalytic activity of the ITK (42). Deletion of PH domain alone 
increases the kcat of ITK by 5 fold (42). Part of this thesis work is dedicated to the 
thorough investigation of role of PH domain on ITK kinase activity (Chapter 3).     
 
7. PH domain 
PH domains are approximately 120 amino acid lipid-binding modules found in 
many proteins involved in signal transduction pathways and cytoskeletal regulation (43). 
This domain binds phosphoinositide within cell membranes. All PH domains are 
structurally conserved but lack primary sequence similarity (44). Three-dimensional 
structures of several PH domains reveal that they share common three-dimensional 
features consisting of two perpendicular anti-parallel beta sheets and C-terminal alpha 
helix (45).  
  
Several structures of PH domains belonging to TEC family kinase (BTK, TEC) 
have been determined and show that the C-terminal Zn2+ binding TH domain is crucial 
for the structural integrity of the PH domain (46, 47). The structure of ITK PH domain 
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has not been solved to date. PH domain of TEC family kinases specifically binds to PIP3 
in the plasma membrane hence recruiting the kinase to the membrane (48). The crystal 
structure of BTK PH domain bound to IP4 the soluble head group of PIP3 is shown in 
Figure 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Crystal structure of BTK PH domain complex IP4 (blue), the soluble headgroup 
of PIP3, PDB ID: 1B55  
 
Along with the canonical role of targeting proteins to the membrane via 
phosphatidylinositol (3,4,5)-triphosphate (PI (3,4,5) P3) binding, PH domains have also 
been implicated in other non- canonical functions, such as mediating protein-protein 
interactions and regulating the activity of the enzymes. Some examples of PH domain 
mediated protein-protein interactions include BTK PH domain interaction with the βγ 
subunit of G protein coupled receptors (49, 50), filamentous actin (51) and Protein kinase 
C (52). Examples of PH domain regulating enzymatic activity include BTK (41) and 
Protein kinase B (PKB/Akt) (53, 54). In both cases, the PH domain is known to interact 
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with kinase domain intramolecularly to autoinhibit the kinase and disruption of this 
interaction is known to enhance the enzymatic activity of both enzymes. 
 
Thesis Organization 
 This thesis dissertation includes five chapters. Chapter 1 provides the general 
introduction and literature review on T cell kinase ITK its substrate PLCγ1 and scaffold 
protein SLP-76 and their roles in T cell receptor signaling. It also reviews the regulatory 
mechanisms of ITK and PLCγ1.  Chapter 2, which has been published in the Journal of 
Molecular Biology, focuses on role of the adaptor protein SLP-76 on regulating the 
conformation of  PLCγ1 for efficient phosphorylation by ITK. Using in vitro experiments 
and NMR titrations, fluorescence titrations, pull down assays and activity assays; we 
were able to describe the mechanism by which SLP-76 pY173 regulates the 
phosphorylation of PLCγ1 by ITK. The results suggest that SLP-76 pY173 interacts with 
the SH2C domain of PLCγ1 regulating the accessibility of Y783 in the linker, for ITK. 
This mechanism is described as a substrate priming mechanism whereby SLP-76 primes 
the PLCγ1 for efficient phosphorylation by ITK. 
  
Chapter 3 is a revised manuscript currently under consideration in Biochemistry. 
The data focus on the characterization of the intramolecular interaction between the ITK 
kinase domain and PH domain and the role of this interaction in regulating ITK kinase 
activity. We have defined a new binding surface on the ITK PH domain that directly 
interacts with the kinase domain and demonstrate that mutations leading to the disruption 
of this regulatory interaction activate ITK. Chapter 4 is a preliminary study of the ITK 
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PH domain and ITK Kinase domain interactions in vivo, using a bimolecular 
fluorescence complementation (BiFC) assay. This study will eventually lead to the 
development of an in vivo screen for small molecules targeting the ITK PH/Kinase 
binding interface. The general conclusion chapter (chapter 5) includes a summary of the 
research work and future directions 
 
Motivation 
This thesis aims to contribute to our understanding the complex regulation 
mechanism of ITK and its substrate PLCγ1. For ITK, this thesis is focused on its N 
terminal PH domain and its role in regulating the ITK enzyme. For PLCγ1, this thesis is 
focused on how PLCγ1 autoinhibitory conformation is disrupted by SLP-76. 
Understanding the regulatory mechanism of this enzyme/substrate pair is valuable for 
targeting these molecules for therapeutic purposes to treat diseases that are linked to ITK. 
Significant effort has been invested for small molecules discovery that target the active 
site of the ITK and other kinases (55-57). However, the common chemical and structural 
environment in the active site of all kinases pose specificity problems. To combat these 
problem, specific allosteric regulatory sites within ITK that govern ITK activity can also 
be targeted. Hence, the study of regulatory interactions that influence the catalytic 
activity of the ITK is crucial. Non-catalytic domains in ITK regulate the ITK kinase 
activity but due to the lack of full length structure, exact mechanism of these regulatory 
domains on how they influence the activity of the ITK are not clear. Hence the 
motivation of this dissertation is to define and characterize the crucial interactions of 
ITK, both intermolecular regulatory interactions (Chapter 2) and intramolecular 
 18 
regulatory interactions (Chapter 3), using a variety of biochemical and biophysical 
techniques. 
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CHAPTER 2 
SCAFFOLD PROTEIN SLP-76 PRIMES PLCγ1 FOR ACTIVATION BY ITK 
MEDIATED PHOSPHORYLATION 
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Abstract 
Activation of the phospholipase, PLCγ1, is critical for proper T cell signaling 
following antigen receptor engagement. In T cells, the Tec family kinase, ITK, 
phosphorylates PLCγ1 at tyrosine 783 (Y783) leading to activation of phospholipase 
function and subsequent production of the second messengers IP3 and DAG.  In this work 
we demonstrate that PLCγ1 can be primed for ITK mediated phosphorylation on Y783 by 
a specific region of the adaptor protein, SLP-76.  The SLP-76 phosphotyrosine containing 
sequence, pY173IDR, does not conform to the canonical recognition motif for an SH2 
domain yet binds with significant affinity to the C-terminal SH2 domain of PLCγ1 
(SH2C).  The SLP-76 pY173 motif competes with the autoinhibited conformation 
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surrounding the SH2C domain of PLCγ1 leading to exposure of the ITK recognition 
element on the PLCγ1 SH2 domain and release of the target tyrosine, Y783. These data 
contribute to the evolving model for the molecular events occurring early in the T cell 
activation process.   
 
Introduction 
 
Activation of phospholipase Cγ1 (PLCγ1) by phosphorylation of Y783 is 
mediated by Interleukin-2 induced tyrosine kinase (ITK) and is a key event following T-
cell receptor (TCR) stimulation (58, 59). Once active, PLCγ1 hydrolyzes 
phosphatidylinositol-4,5-bisphosphate (PIP2) to produce inositol 1,4,5-triphosphate (IP3) 
and diacylglycerol (DAG); second messengers that control calcium flux from the 
endoplasmic reticulum and activation of Protein kinase C, respectively (60).  A number 
of additional signaling molecules participate in activation of PLCγ1, in particular the 
scaffolding functions of SLP-76 (SH2 domain-containing leucocyte protein of 76 kDa) 
(61), LAT (linker for activation of T cells) (62) and Gads (Grb2-related adaptor 
downstream of Shc) (63) play important roles in co-localization of ITK and PLCγ1 (33).  
Specific contacts among the proteins in this T cell signaling complex have been identified 
and characterized providing glimpses into the molecular mechanisms by which TCR 
signals are propagated.   
 
ITK and PLCγ1 are both multi-domain containing proteins that have Src 
homology 2 (SH2) and Src homology 3 (SH3) domains in addition to their catalytic 
domains (Fig. 1a). Binding sites for the SH2 and SH3 adaptor domains of ITK and 
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PLCγ1 have been identified on both SLP-76 and LAT.  Specifically, the PLCγ1 SH3 
domain and N-terminal SH2 domain (SH2N) bind to the proline-rich region of SLP-76 
and the LAT phosphotyrosine 132 (pY132), respectively (64, 65).  The ITK SH2 domain 
binds one of three well-characterized phosphotyrosine sites (35) in the N-terminal half of 
SLP-76 (Fig. 1); pY145 is the target of ITK SH2 (36, 66) while SLP-76 pY112 and 
pY128 bind to SH2 domains within the signaling molecules, Vav and Nck (67-70).  In 
addition to these canonical Src homology domain mediated interactions, a direct substrate 
docking interaction between ITK and PLCγ1 occurs via a phosphotyrosine independent 
mechanism involving the C-terminal SH2 domain (SH2C) of PLCγ1 and the ITK kinase 
domain (30). The PLCγ1 SH2C domain docks onto the C-lobe of the ITK kinase domain 
creating an enzyme/substrate recognition complex required for efficient phosphorylation 
of PLCγ1 Y783 (31, 32).  Clearly, a large number of distinct protein-protein interactions 
(Fig. 1b) are present within the complex web of signaling interactions required for proper 
signal transduction in the T cell (71-73) and it is likely that additional interactions, 
including those not yet described, also contribute to the pathway. Indeed, a recent finding 
points to another regulatory phosphorylation site in the N-terminal region of SLP-76 at 
Y173 (34); this newly recognized phosphotyrosine is adjacent to the pY112, pY128 and 
pY145 sites.  
 
Sela et al. (34) demonstrate that phosphorylation at Y173 within SLP-76 is 
required for TCR induced phosphorylation of PLCγ1.  A detailed mechanistic 
explanation for this observation is currently lacking but the authors in the original work 
speculate that SLP-76 pY173 may bind to the SH2C domain of PLCγ1 to facilitate 
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docking of PLCγ1 onto the ITK domain (34).  The kinase docking site and 
phosphotyrosine binding pocket form distinct surfaces on the PLCγ1 SH2C domain and it 
is therefore possible that binding of SLP-76 pY173 to PLCγ1 SH2C may enhance 
ITK/PLCγ1 docking.  We have previously shown, however, that the interaction of PLCγ1 
SH2C with the ITK kinase domain is unaffected by phosphopeptide binding to PLCγ1 
SH2C (31) and so an allosteric role for SLP-76 pY173 facilitating docking can be ruled 
out.  Co-localization of ITK and PLCγ1 at adjacent sites on SLP-76 may enhance ITK 
mediated phosphorylation of PLCγ1 at Y783 but PLCγ1 makes multiple contacts within 
the signaling complex (PLCγ1 SH3/SLP-76; PLCγ1 SH2N/LAT) and Sela et al. show 
that mutation of Y173 does not reduce association of ITK or PLCγ1 with SLP-76 in T 
cells (34).  Moreover, it has been observed that a loss of function mutation in the SH2C 
domain within full length PLCγ1 does not significantly affect recruitment of PLCγ1 to 
the SLP-76 signaling complex yet PLCγ1 Y783 phosphorylation, and hence PLCγ1 
activity, is decreased significantly (74).  
 
Here we pursue a detailed model to explain the role of SLP-76 pY173 in T cell 
signal transduction.  We test the hypothesis that SLP-76 pY173 alters the inhibitory 
conformation of PLCγ1 (75) thereby priming PLCγ1 for activation by ITK.  Our findings 
show that, in spite of a non-classical SH2 binding motif, the SLP-76 derived 
phosphopeptide surrounding pY173 binds to PLCγ1 SH2C, disrupting an intramolecular 
PLCγ1 inhibitory complex, leading to release of PLCγ1 Y783 for more efficient 
phosphorylation by ITK.  The data provided here add to our evolving view of the 
molecular events controlling antigen receptor stimulated activation of PLCγ1. 
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Results  
The unphosphorylated Y783 containing linker in PLCγ1 associates intramolecularly with 
the adjacent SH2C domain in solution.   
The structure of the SH2N-SH2C-linker fragment of PLCγ1 has been recently 
solved (29) and reveals a specific intramolecular contact between the PLCγ1 linker 
region that contains Y783 and the SH2C domain (Fig. 2a). A large stretch of the PLCγ1 
linker region is not defined by the electron density, but Y783 and the following six amino 
acids (Y783VEANPM) are defined and form contacts with the pY+3 binding pocket of 
SH2C (Fig. 2a).  We first wished to assess the extent to which the Y783 linker region 
associates with PLCγ1 SH2C in solution.  Using NMR spectroscopy, we acquired 1H-15N 
HSQC data for the PLCγ1 SH2C domain alone and the longer PLCγ1 SH2C-linker 
protein (Fig 2b). Extensive differences in the chemical shifts of the SH2C NMR 
resonances are observed upon comparing spectra of PLCγ1 SH2C and SH2C-linker, 
consistent with association between the linker region and the SH2C domain.  Linewidths 
(and therefore rotational correlation times) are very similar for both proteins indicating 
the linker region contacts SH2C in an intramolecular manner.  Thus, solution NMR data 
appears consistent with the SH2C/linker association observed in the crystal structure. 
 
Extensive chemical shift differences between the backbone amide resonances of 
SH2C and SH2C-linker are observed (Fig. 2b). It is likely that, in addition to 
intramolecular contacts between linker and SH2C, covalent extension of the C-terminus 
of SH2C to form SH2C-linker contributes to the observed spectral differences. 
Nevertheless, we can unequivocally identify the SH2C resonances that do not change 
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when compared to SH2C-linker and the remaining SH2C resonances are therefore either 
directly or indirectly affected by the presence of the Y783 containing linker.  Mapping 
the spectral changes onto the SH2C domain within the PLCγ1 SH2N-SH2C-linker crystal 
structure shows that the most contiguous regions giving rise to spectral differences upon 
linker association correspond to regions of the SH2C domain that directly contact the 
linker in the crystal structure (Fig. 2c).  
 
To further examine the solution conformation of PLCγ1 SH2C-linker, we probed 
the contribution of specific residues C-terminal to Y783 since these side chains make 
contacts to SH2C in the crystal structure (Fig. 2a).  We constructed an SH2C-linker 
variant where N787, P788 and M789 are mutated to alanine (PLCγ1 SH2C-linker 
NPM_AAA) and acquired 1H-15N HSQC data. The SH2C-linker resonances shift 
significantly in the mutant protein to positions that are nearly coincident with the 
resonances of PLCγ1 SH2C alone (Fig. 2d and supplementary figure 1) suggesting that 
the C-terminal residues of SH2C-linker (N787P788M789) stabilize linker association in 
solution. Finally, using size exclusion chromatography, we find that the retention time of 
the mutant PLCγ1 SH2C-linker (N787P788M789_AAA) is less than wild type SH2C-linker, 
suggesting the NPM to AAA mutation releases the linker from the SH2C interaction, 
increasing the apparent size of the SH2C-linker protein (Fig. 2e).  Together, these data 
provide evidence that the SH2C-linker region in PLCγ1 adopts an intramolecular 
complex in solution that resembles that observed in the available crystal structure.  
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Intramolecular SH2C-linker association limits docking of the PLCγ1 substrate to the ITK 
kinase domain. 
Efficient PLCγ1 phosphorylation by ITK in T cells depends on a docking 
interaction between PLCγ1 SH2C and the ITK kinase domain; PLCγ1 SH2C binds to the 
C-lobe of the ITK kinase domain in a phosphotyrosine independent manner via side 
chains in the CD loop and C-terminus of SH2C (Fig. 3a). The PLCγ1 linker region 
associates with SH2C in a region that is nearly coincident with the kinase-docking site we 
have mapped previously (31).  The proximity of PLCγ1 linker bound to SH2C and the 
recognition motif required for ITK docking prompted us to test the effect of the PLCγ1 
linker on ITK kinase domain/PLCγ1 SH2C domain association.  In a pull down 
experiment using immobilized GST fusions of PLCγ1 SH2C and SH2C-linker, we find 
that the ITK kinase/PLCγ1 SH2C domain interaction is stronger in the absence of the 
PLCγ1 linker sequence (Fig. 3b).  Taken together with the data supporting the 
intramolecular complex seen in the PLCγ1 crystal structure, we interpret these data to 
suggest that the intramolecular association between SH2C and linker region competes 
with binding of PLCγ1 SH2C to the ITK kinase domain. 
 
Despite unusual flanking sequence, the SLP-76 pY173 peptide binds to the PLCγ1 SH2C 
domain. 
Like the PLCγ1/ITK substrate/kinase docking interaction, the intramolecular 
interaction between the Y783 linker and SH2C domain is independent of tyrosine 
phosphorylation.  In spite of the absence of phosphorylation on Y783, the interaction of 
the linker with SH2C bears a resemblance to the structure of a canonical phosphotyrosine 
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ligand bound to the PLCγ1 SH2C domain (Figs. 2a, 3c).   The bound linker and pY 
containing peptide are nearly superimposable and in both cases the ‘specificity pocket’ or 
pY+3 pocket of SH2C mediates direct contacts with residues C-terminal to the tyrosine 
(pY or Y783) (Fig. 3d).  A difference between the two complexes occurs at the pY-
binding pocket.  In the SH2/phosphopeptide structure this pocket is filled by the pY side 
chain of the peptide ligand but the SH2C pY pocket remains empty in the structure of 
PLCγ1 SH2N-SH2C-linker without Y783 phosphorylation (Fig. 3d, inset).   
 
Given the overlap in binding sites on the PLCγ1 SH2C domain for the 
unphosphorylated linker and a phosphopeptide ligand, we hypothesize that the pY173 
containing phosphopeptide derived from SLP-76 competes with intramolecular linker 
binding to destabilize the autoinhibited form of PLCγ1. The SLP-76 sequence, pY173-I-D-
R, contains an arginine instead of the canonical/preferred hydrophobic residue in the 
pY+3 position (76) and so we first tested binding of the SLP-76 sequence to PLCγ1 
SH2C. Titration of unlabeled SLP-76 peptide, N-S-M-pY173-I-D-R-P-P-T-G-K, into 15N 
labeled PLCγ1 SH2C was carried out with acquisition of 1H-15N HSQC spectra at each 
point in the titration (Fig. 4a).  Chemical shift changes are measured for each amide NH 
resonance in the SH2C domain (Fig. 4b) and the largest changes are visualized on the 
structure of PLCγ1 SH2C (Fig. 4c). The resonance changes induced by addition of the 
SLP-76 peptide localize to the pY and pY+3 pockets as would be expected for a 
canonical interaction between phosphotyrosine peptide and SH2 domain (Fig. 4c). The 
unusual presence of arginine in the pY+3 position prompted us to model this residue into 
the structure of PLCγ1 SH2C bound to a canonical phosphopeptide.   Superposition of the 
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Cα-Cβ bond of arginine onto that of proline in the structure shown in Figure 3c suggests 
that the hydrophobic residues lining the pY+3 pocket may create favorable interactions 
with the aliphatic portion of the arginine side chain much as they do with the proline in 
the pY+3 position (Fig. 4d). In addition, the model suggests the possibility of favorable 
cation-pi interactions (77) between the guanidinium group of the arginine side chain and 
two adjacent tyrosines, Y740 and Y741, deep in the pY+3 pocket of SH2C (Fig. 4d). 
Experimental structure determination will be needed to confirm this model but it is 
interesting to speculate that certain SH2 domains may be capable of broader ligand 
recognition within the pY+3 pocket.  The only other report of an arginine occupying the 
pY+3 position in an SH2 domain phospholigand comes from a large proteomics study 
testing the binding propensity of predicted ligands to various SH2 domains (Supp Fig S4 
in (78)).  The sequence pYDTR binds to the Crk SH2 domain, which contains FY at the 
position corresponding to Y740 and Y741 in PLCγ1 SH2C.  It is also notable that only a 
subset of SH2 domains contain the YY or FY motif, suggesting the potential for a 
specific recognition mechanism for pY target sequences with arginine in pY+3 position 
(79).  Finally, to quantify the affinity of the unusual SLP-76 pY173 peptide binding to 
PLCγ1 SH2C, we measured fluorescence as a function of increasing pY173 peptide 
concentration and determined a dissociation constant of 1.6 µM (Fig. 4e). 
 
Binding of SLP-76 pY173 to PLCγ1 SH2C releases the Y783 containing linker and 
unmasks the kinase docking site on SH2C. 
Having determined that the Slp76 derived pY173 phosphopeptide binds to the 
PLCγ1 SH2C domain, we next examined the effect of this phosphopeptide on the 
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intramolecular PLCγ1 SH2C/linker association.  Using dynamic light scattering, we 
compared the size distribution for PLCγ1 SH2C-linker and SH2C-linker plus the SLP-76 
pY173 peptide.  The mutant SH2C-linker (N787P788M789_AAA) is used as a control for 
near complete linker displacement based on the data in Figure 2.  Of the three PLCγ1 
fragments, SH2C-linker, peptide bound SH2C-linker and the mutant SH2C-linker, the 
PLCγ1 SH2C-linker protein is the most compact structure with an average hydrodynamic 
radius of 2.0 nm (Fig. 5a).  The size distributions for both the mutant SH2C-linker 
(N787P788M789_AAA) and SH2C-linker plus SLP-76 pY173 peptide shift to larger particle 
size; an increase of 12-25% over the SH2C-linker protein (average hydrodynamic radii of 
2.25 and 2.5 nm).  These data suggest that the pY173 peptide displaces the linker in a 
manner similar to mutation of the linker itself leading to a more disengaged stretch of 
amino acids surrounding PLCγ1 Y783.  In a separate experiment, addition of increasing 
SLP-76 pY173 peptide to the 15N-labeled sample of PLCγ1 SH2C-linker (Fig. 5b) reveals 
NMR chemical shift changes toward the resonances of the pY173 peptide bound SH2C 
spectrum (Fig. 5c). Thus, the SLP_76 pY173 peptide ligand binds to PLCγ1 SH2C-linker 
in a manner that is nearly identical to the isolated SH2C domain albeit with slightly lower 
affinity, Kd = 2.9 µM compared to a Kd = 1.6 µM for the pY173/SH2C interaction (Fig. 
5d, 4e). All of these data are consistent with a model where SLP-76 phosphopeptide 
binding to PLCγ1 SH2C directly competes with and releases the PLCγ1 linker region 
containing Y783 resulting in exposure of the kinase docking site on PLCγ1 SH2C and 
increased accessibility of PLCγ1 Y783 for the ITK kinase.  
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SLP-76 pY173 enhances the ITK phosphorylation of PLCγ1 
 To assess the effect of SLP-76 pY173 on the ITK mediated phosphorylation of 
PLCγ1 Y783, we carried out an in vitro kinase assay subjecting full length PLCγ1 to 
phosphorylation by full length ITK.  An antibody specific to PLCγ1 pY783 is used to 
detect phosphorylation at the PLCγ1 783 position following incubation of the PLCγ1 
substrate with active ITK (Fig. 6).  Consistent with PLCγ1 adopting an autoinhibited 
form, we find that in vitro phosphorylation efficiency of Y783 in full length PLCγ1 is 
quite poor; pY783 levels are not different than background levels detected for the PLCγ1 
substrate alone (Fig. 6a, lanes 2 & 3). The same in vitro kinase assay is next carried out 
with increasing concentration of the SLP-76 derived phosphopeptide, N-S-M-pY173-I-D-
R-P-P-T-G-K (Fig. 6a, lanes 4-7).  Quantification of the pY783 levels shows that 
increasing SLP-76 pY173 peptide increases the extent of PLCγ1 pY783 phosphorylation 
by ITK (Fig. 6b).   Smaller fragments of PLCγ1, P-SH2N-SH2C-linker-SH3-H and 
SH2C-linker, show the same trend (Fig. 6c-f).  Increased concentration of the SLP-76 
pY173 peptide causes an increase in ITK mediated PLCγ1 phosphorylation on Y783. For 
the smallest Y783 containing PLCγ1 fragment, SH2C-linker, we tested the importance of 
the pY binding pocket by mutation of R694 to alanine (Fig. 6e,f).   Disruption of the 
PLCγ1 SH2C binding pocket by mutation results in no increase in Y783 phosphorylation 
by ITK upon addition of the SLP-76 pY173 peptide (Fig. 6e,f).  These data directly 
implicate the PLCγ1 SH2C domain in the observed enhancement and show that addition 
of the SLP-76 pY173 peptide to the kinase assay is not simply activating ITK (by binding 
to the ITK SH2 domain).  This latter point is consistent with our previous observations 
that pY containing peptides do not increase ITK kinase activity toward a generic peptide 
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substrate (unpublished data).  Collectively, our findings point to a SLP-76 dependent 
priming model for PLCγ1 activation by ITK.  The SLP-76 pY173 sequence binds to the 
PLCγ1 SH2C domain, disfavoring the autoinhibited conformation, which renders PLCγ1 
a better substrate for ITK. 
 
Discussion 
ITK mediated phosphorylation of Y783 in PLCγ1 occurs in the context of a multi-
component signaling cluster that includes the scaffold protein SLP-76 in addition to a 
number of others proteins (LAT, Vav, Nck, GADS) (Fig. 7).  Our data provide support 
for an autoinhibited conformation of PLCγ1 in solution that is consistent with the 
reported crystal structure of the SH2N-SH2C-linker region of PLCγ1 (29).  We find that 
the autoinhibited form of PLCγ1 shields the kinase-docking site on the PLCγ1 SH2C 
domain (31) and limits access to the substrate tyrosine, Y783 (Fig. 7a).  Our data also 
suggest that the most recently characterized phosphorylation site on SLP-76, pY173, can 
prime PLCγ1 for phosphorylation by ITK.  The SLP-76 pY173 containing 
phosphopeptide can bind to the PLCγ1 SH2C domain (in spite of the non-canonical 
arginine in the pY+3 position), releasing the PLCγ1 linker region from SH2C to reveal 
both the ITK kinase-docking site on PLCγ1 SH2C and the substrate tyrosine, Y783 (Fig. 
7a,b). These conformational changes away from the autoinhibited form of PLCγ1 would 
predispose the PLCγ1 molecule for efficient phosphorylation by ITK.  Once PLCγ1 is 
phosphorylated, an intramolecular interaction between pY783 and SH2C (80, 81) can 
compete with the PLCγ1 SH2C/SLP-76 pY173 interaction and displace PLCγ1 from the 
SLP-76/ITK signaling complex allowing another round of ITK mediated catalysis to 
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proceed (Fig. 7c).  This final step is consistent with recent observations that activated 
PLCγ1 rapidly moves away from the ITK/LAT/SLP-76 complex to the TCR cluster (82). 
Also, the affinity we measured for PLCγ1 SH2C and SLP-76 pY173 interaction is 
relatively weaker for SH2 interaction and this weaker interaction possibly makes PLCγ1 
SLP-76 interaction more transient and activated PLCγ1 can dislocate rapidly from 
ITK/LAT/SLP-76 complex.  The extent to which the other adaptor domains (PH, SH2N, 
SH3, C2) within PLCγ1 also play a role in mediating release of active PLCγ1 from the 
ITK/SLP-76/LAT complex is not clear and must be considered in any evolving model of 
T cell activation.  Finally, it is notable that complete loss of the SLP-76 pY173 site has 
no measureable effect on assembly of the signaling complex in T cells yet has a profound 
effect on the extent to which PLCγ1 is activated. Our biochemical results underscore the 
importance of how a substrate is presented to its cognate kinase; signaling molecules 
must not only assemble into a productive complex but must also be able to access the 
precise conformational state required for productive signal transduction.  
 
The SLP-76 phosphoprotein combines its well-known scaffold function with a 
regulatory role in the form of conformational priming of PLCγ1.  Previously published 
findings suggested that SLP-76 is required to activate ITK by maintaining an active 
conformation of the kinase (83).  While interactions between SLP-76 pY145 and the ITK 
SH2 domain are required for proper T cell signaling (36), we have never been able to 
observe any direct effect of SLP-76 derived phosphopeptides on the in vitro kinase 
activity of ITK (unpublished data, A.H.A. and Xiaoguang Qu).  Since the previously 
mentioned experiments pointing to a role for SLP-76 in activating ITK (83) made use the 
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PLCγ1 SH2N-SH2C-linker-SH3 substrate to probe ITK catalytic activity, it is possible 
that the activating effect that was observed is due to the role of SLP-76 in priming PLCγ1 
for phosphorylation rather than activation of ITK catalytic activity per se.   
 
There are numerous additional domain interactions that mediate formation of the 
signaling complexes involving PLCγ1 and ITK and so the evolving picture for PLCγ1 
SH2C and SLP-76 pY173 must be considered as part of a larger set of regulatory 
interactions. A newly described protein-protein interaction regulating B-cell signaling 
implicates calcium dependent binding of the PLCγ2 C2 domain and pY119 in Slp-65 (the 
B-cell scaffolding protein related to the T cell expressed SLP-76) (84). Given the 
sequence similarities surrounding Slp-65 pY119 (EpY119IDNR) and SLP-76 pY173, 
(MpY173IDRP), the finding in B cells prompted us to consider whether the 
conformational priming of PLCγ1 we have characterized here could involve the PLCγ1 
C2 domain. First we note that the SLP-76 driven amplification of PLCγ1 phosphorylation 
occurs even for the smallest fragments of PLCγ1 containing just SH2C and linker 
suggesting that C2 is not mediating the observed increase in pY783 levels (Fig. 6). It is 
also of note that the Slp-65 derived phosphopeptide does not bind full length PLCγ1 (84) 
suggesting that the Slp-65 phosphotyrosine motif, pYIDN, does not bind the PLCγ1 C2 
domain and may not even bind well to PLC SH2 domain(s) leaving this Slp-65 site 
available to regulate B cell signaling in a manner quite different from the related site in 
SLP-76.  Our data further suggest that the motif surrounding pY173 in SLP-76 (pYIDR) 
is tuned to bind specific SH2 domains; in particular the unusual presence of arginine in 
the pY+3 position may steer the SLP-76 phosphotyrosine motif toward binding SH2 
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domains (such as PLCγ1 SH2C) that can accommodate the long and positively charged 
arginine in this position.  Thus, despite what appear to be sequence similarities in the 
proteins that regulate T- and B-cell signaling cascades, we are finding that very different 
mechanistic rules may apply to these distinct immune signaling systems. 
 
Substrate priming has not, to our knowledge, been previously ascribed to the SLP-
76 molecule. Since its identification in 1995 (85), SLP-76 has been well characterized as 
a scaffold protein and its role in recruiting and co-localizing multiple signaling proteins 
in T cells is undisputed.  Our findings now suggest that SLP-76 may also play a role in 
directly regulating the apparent enzymatic activity emanating from the T cell receptor 
proximal Tec kinase, ITK.  Substrate priming has been well described in other systems. 
One example is glycogen synthase; hierarchical phosphorylation events prime glycogen 
synthase for phosphorylation (and activation) by glycogen synthase kinase (86-88).   
Another example involves the RING ubiquitin ligases; a conformational shift away from 
an autoinhibited state coupled with tyrosine phosphorylation comprise integral 
components of the regulatory mechanisms controlling ubiquitin transfer (89-92).  
Dissecting the biochemical steps within the trio of T cell signaling proteins, SLP-76, ITK 
and PLCγ1, has uncovered a possible role for SLP-76 pY173 in promoting PLCγ1 
activation in T cells by conformational priming. The next stage in advancing our 
understanding of how productive signaling complexes are formed in T cells will require 
significant effort in reconstituting larger, multi-component complexes that can 
recapitulate the signaling steps present in the cell.    
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Materials and Methods 
Constructs 
Baculoviral expression constructs of full-length ITK (mouse) and rat full-length PLCγ1 
(rat) have been described previously (93). The fragments of PLCγ1 SH2C, SH2C-linker 
and P-SH2N-SH2C-linker-SH3-H were amplified by polymerase chain reaction and 
cloned to pGEX-4T-1 expression vector (GE Healthcare). The SH2C R694A mutation 
was introduced by site directed mutagenesis (Stratagene). All sequences were verified by 
sequencing at the Iowa State University DNA synthesis and sequencing facility. 
 
Protein/peptide Production and Purification 
Full-length ITK and PLCγ1 were expressed in Sf9 cells and were purified as described 
previously (93). Similarly, PLCγ1 SH2C and SH2C-linker were expressed in E. coli 
BL21 cells and purified as described previously (30). For P-SH2N-SH2C-linker-H, 
bacterial cell pellets were re-suspended in lysis buffer consisting of 50mM Tries, pH 8 
and 150 mM NaCl and lysed by treating with lysozyme (0.5 mg/ml). Cleared lysate was 
applied to a Glutathione Sepharose column (GE Healthcare) equilibrated with lysis 
buffer. The GST-tagged P-SH2N-SH2C-linker-H protein was eluted with lysis buffer 
containing 10 mM glutathione and the GST tag was cleaved by treatment with Thrombin 
(Sigma) for 5 minutes at room temperature. The cleavage reaction was stopped with 
1mM PMSF, and the cleaved protein was applied to a HiLoad Superdex 200 prep grade 
column to separate GST from the desired PLCγ1 P-SH2N-SH2C-linker-H protein. The 
SLP-76 pY173 peptide with sequence Ac-NSMpY173IDRPPTGK-NH2 was synthesized 
and purified by GenScript.  
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NMR Spectroscopy 
NMR spectra were collected on a Bruker AVII 700 spectrometer with a 5mm HCN z-
gradient cryoprobe operating at a 1H frequency 700.13 MHz at 298K. NMR titration 
experiments were carried out by acquiring 1H-15N HSQC spectra of 250 µM SH2C or 
SH2C-linker within increasing SLP-76 pY173 peptide concentration: 0, 39.9, 79.9, 159.1, 
238, 355.7, 722.18, 1273, 1982 µM. The chemical shift changes in PLCγ1 SH2C induced 
by addition the SLP-76 pY173 peptide were quantified by using the following equation: 
Δδave = {[½ [(ΔδH)2 + (0.2ΔδN)2]}1/2 (94). Residues with chemical shift changes above 
the mean plus one standard deviation were considered significant. Buffer composition 
used to solubilize the SLP-76 pY173 peptide is identical to the protein buffer (50mM 
KH2PO4, pH 6.4, 150 mM NaCl, 2mM DTT and 0.02% NaN3).  
 
Fluorescence Spectroscopy  
 Tryptophan fluorescence for 3 µM PLCγ1 SH2C or SH2C-linker with increasing 
concentration of the SLP-76 pY173 peptide was measured using a Cary eclipse 
spectrophotometer at 250C.  The wavelength used for tryptophan excitation was 295nm 
while emission was recorded between 300-400 nm. All measurements were carried out in 
triplicate. The maximum fluorescence intensity for each titration point was plotted 
against ligand concentration and the dissociation constant (Kd) was calculated by fitting 
the data in MATLAB using the equation:  I = I0 + ΔI  * [[(Kd + P + L) - {(Kd+P +L) 2 – 
4P*L} 1/2]/2P] (95), where I is fluorescence intensity, I0 is fluorescence intensity of 
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protein without any ligand, ΔI is change in fluorescence intensity on ligand binding, Kd is 
dissociation constant, P is protein concentration and L is ligand concentration.   
 
Dynamic light scattering 
Hydrodynamic radii of 50 µM PLCγ1 SH2C-linker, 1:1 ratio of SH2C-linker + SLP-76 
pY173 peptide, and SH2C-linker NPM_AAA mutant in buffer containing 50mM 
KH2PO4  pH 6.4, 150 mM NaCl, 2mM DTT and 0.02% NaN3 were measured using a 
DynaPro® NanoStarTM light scattering instrument (Wyatt Technology) at 250C.  
 
Kinase assays and western blotting 
In vitro kinase assays were performed using full-length ITK and various substrate 
constructs of PLCγ1 (0.1 µM Full length PLCγ1, 0.1 µM P–SH2N-SH2C-linker-SH3-H, 
1 µM SH2C-linker, 1 µM SH2C-linker R694A) with the increasing concentration of 
synthetic SLP-76 pY173 peptide.  Kinase assay buffer consisted of 50mM HEPES pH 
7,10mM MgCl2, 1 mM DTT, 1mg/ml BSA, 1mM Pefabloc, and 200 µM ATP. PLCγ1 
substrates and SLP-76 pY173 peptide were preincubated for 20 minutes prior to addition 
of the ITK enzyme. Kinase reactions were carried out for one minute for full length 
PLCγ1 and P–SH2N-SH2C-linker-SH3-H substrates and five minutes for SH2C-linker 
and SH2C-linker R694A.  Upon	   completion	   of	   the	   kinase	   reaction,	   samples	   were	  boiled,	   separated	   by	   SDS-­‐PAGE	   and	  western	   blotted	  with	   the anti pY783 antibody 
(EMD Millipore) for the detection of pY783 levels in each PLCγ1 substrate. Anti ITK 
(2F12) (Thermo Scientific) and Strep	   Tag	   II	   Monoclonal	   antibody	   (EMD	  Millipore) 
 43 
were used to detect total level of ITK and full length PLCγ1 respectively. Smaller 
fragments of PLCγ1 were detected by Coomassie staining.  
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Figure Captions: 
Figure 1. Domain structures and schematic of interactions for the signaling proteins that 
assemble downstream of the T cell receptor. (a) ITK, PLCγ1 and SLP-76 domain maps, 
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PLCγ1 Y783 is indicated within the 33-residue linker between the SH2C and SH3 
domains of PLCγ1.  The fourth phosphorylation site on SLP-76, Y173, is circled and the 
Proline-Rich Region of SLP-76 is indicated as PRR (SLP-76 Y112, Y128 and Y145 have 
been previously characterized and serve as binding sites for Vav, Nck and Itk when 
phosphorylated).  (b) Schematic of the T cell signaling complex involving the proteins in 
the current study: ITK, PLCγ1 and SLP-76 as well as LAT, Vav, Nck and Gads (not 
included in this study). The dashed double-headed arrow indicates the SLP-76 pY173/ 
PLCγ1 SH2C interaction described in the current study. Solid, double-headed arrows 
indicate characterized interactions between specific domains of ITK, PLCγ1, SLP-76 and 
LAT that are discussed in the text.  Asterisks (*) denote canonical SH3 or SH2 mediated 
interactions involving proline-rich (PXXP) or phosphotyrosine (pY) motifs, respectively. 
The lighter gray arrow indicates the phosphotyrosine-independent docking interaction 
between PLCγ1 SH2C and ITK kinase domains that is required for phosphorylation of 
PLCγ1 by ITK.   
 
Figure 2. Solution data is consistent with the autoinhibited PLCγ1 conformation observed 
in the crystal structure.  (a) Crystal structure of the PLCγ1 SH2N-SH2C-linker fragment 
(PDB ID: 4FBN).  The SH2N and SH2C domains are gray and the linker region is cyan.  
The resolved linker residues surrounding and including Y783 are labeled.  The N-
terminal region of the PLCγ1 linker is also resolved and adopts a helical segment. The 
intervening eleven residues in the linker are not resolved in the crystal structure and are 
indicated by a dashed line.  (b) Superposition of 1H-15N HSQC spectra for PLCγ1 SH2C 
(blue) and PLCγ1 SH2C-linker (cyan).  (c) Structure of the PLCγ1 SH2C-linker region 
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extracted from the structure shown in (a).  Linker is cyan, black indicates SH2C residues 
for which no chemical shift difference is observed and light gray shows SH2C residues 
for which chemical shift changes are observed when spectra of SH2C and SH2C-linker 
are compared (see (b)). (d) Superposition of three 1H-15N HSQC spectra: PLCγ1 SH2C-
linker (cyan), mutant PLCγ1 SH2C-linker NPM_AAA (red), and PLCγ1 SH2C (blue).  
The resonances for two representative residues highlighted in green in PLCγ1 SH2N-
SH2C-linker structure in a, (H714 and G727) are shown to illustrate the similarity 
between spectra of the mutant PLCγ1 SH2C-linker NPM_AAA and the isolated SH2C 
domain. (e) Size exclusion chromatography (top) showing the elution volume for PLCγ1 
SH2C (solid line), SH2C-linker (dotted line) and mutant SH2C-linker NPM_AAA 
(dashed line).  SDS-PAGE (bottom) showing the purity of the wild type and mutant 
SH2C-linker proteins. 
 
Figure 3. Kinase docking site and intramolecular linker association site on PLCγ1 SH2C 
are partially coincident.  (a) Surface rendition of PLCγ1 SH2N-SH2C-linker showing the 
kinase docking site on SH2C (orange, comprised of the CD loop and C-terminal region of 
the SH2 domain) required for ITK mediated phosphorylation of PLCγ1 Y783, location of 
the intramolecular linker association with SH2C (cyan), and the SH2N domain 
(receding).  (b) Duplicate pull-down experiments showing diminished association of the 
FLAG tagged ITK kinase domain with PLCγ1 SH2C-linker compared to PLCγ1 SH2C. 
Anti-FLAG antibody shows level of associated ITK kinase domain and Ponceau S shows 
total levels of GST-SH2C and GST-SH2C-linker. (c) Ribbon structure of PLCγ1 SH2C 
domain bound to a canonical phosphotyrosine containing peptide (PDB ID: 2PLD).  
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Phosphopeptide ligand is red and the pY and pY+3 residues are labeled. (d) Overlay of 
the phospholigand bound SH2C structure shown in (c) and the SH2C-linker portion of 
the PLCγ1 SH2N-SH2C-linker structure.  The phosphopeptide, pYIIP, is red and the 
PLCγ1 linker region containing Y783 is cyan. The pY+3 pocket is circled and the pY 
pocket is boxed and enlarged in the inset showing the different conformations of the pY 
and Y783 side chains. 
 
Figure 4. The SLP-76 pY173 containing peptide binds the PLCγ1 SH2C domain.  (a) 
Superposition of HSQC spectra from the NMR titration of PLCγ1 SH2C with increasing 
concentration of the SLP-76 pY173 peptide. Spectra are overlaid with light to dark blue 
scheme with increasing SLP-76 pY173 peptide concentration.  (b) Chemical shift 
deviations (Δδ) for each of the PLCγ1 SH2C domain residues upon binding of pY173 
phosphopeptide.  The average deviation (0.1 ppm) is indicated by the horizontal dashed 
line. (c) Residues for which Δδ > 0.1 ppm are indicated in red on the structure of PLCγ1 
SH2C domain. (d) left panel shows the pY+3 pocket in the structure of PLCγ1 SH2C 
bound to a peptide containing proline at the pY+3 position (PDB ID: 2PLD, peptide 
ligand is cyan). Right, model of SH2C/peptide complex containing arginine in place of 
proline in the pY+3 position.  Y740 and Y741 are labeled.  (e) Fluorescence titration 
curve of the SLP-76 pY173 phosphopeptide binding to PLCγ1 SH2C.  
 
Figure 5. (a) Dynamic light scattering data for PLCγ1 SH2C-linker (filled diamonds, 
solid line), mutant SH2C-linker NPM_AAA (filled squares, dotted line) and SH2C-linker 
+ SLP-76 pY173 peptide (filled triangles, dashed line).  (b) Superposition of HSQC 
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spectra from the NMR titration of PLCγ1 SH2C-linker with increasing concentration of 
the SLP-76 pY173 peptide. Spectra are overlaid with light to dark blue scheme with 
increasing SLP-76 pY173 peptide concentration (c) Peaks corresponding to the residues 
of SH2C in the context of SH2C-linker with increasing concentration of SLP-76 pY173 
peptide (light to dark) superimposed with peak of same residue (red) when SH2C is fully 
bound to SLP-76 pY173 peptide. (d) Fluorescence titration curve of the SLP-76 pY173 
phosphopeptide binding to PLCγ1 SH2C-linker. 
 
Figure 6. SLP-76 pY173 enhances ITK mediated phosphorylation of PLCγ1 at Y783. (a) 
Lanes 1 and 2 contain enzyme alone and substrate alone, respectively. Phosphorylation of 
full length PLCγ1 by full length ITK in the absence of SLP-76 pY173 peptide (lane 3) 
and in the presence of increasing concentration of the SLP-76 pY173 peptide (lanes 4-7). 
In (a), (c) and (e), phosphorylation of Y783, ITK enzyme levels and substrate levels are 
detected using anti pY783, anti ITK, and either anti Strep antibody (a) or Coomassie stain 
(c,e). (b) Histogram representation of pY783 level from three independent experiments 
and error bar for pY783 level indicates the standard deviation. Intensity of pY783 level in 
the kinase reaction that lacks SLP-76 pY173 is normalized to 1. (c) Kinase assay using 
the smaller PLCγ1substrate fragment, P-SH2N-SH2C-linker-SH3-H, with increasing 
concentration of SLP-76 pY173 peptide as in (a). (d) Histogram representation of pY783 
level from three independent experiments using PLCγ1 P-SH2N-SH2C-linker-SH3-H as 
substrate. (e) Comparison of pY783 level in PLCγ1 SH2C-linker (wt) and the SH2-linker 
R694A mutant with increasing concentration of the SLP-76 pY173 peptide. (f) Histogram 
 54 
representation of pY783 level from three independent experiments using SH2C-linker 
wild type and SH2C-linker (R694A) mutant. 
 
Figure 7.  Model for priming of PLCγ1 by SLP-76 for phosphorylation and activation by 
ITK.  (a) PLCγ1 is depicted in its autoinhibited conformation where the linker between 
SH2C and SH3 domains is intramolecularly engaged with SH2C, shielding Y783 and the 
kinase docking site on SH2C. T cell activation leads to phosphorylation of SLP-76 
tyrosines such as Y145 creating a binding site for the ITK SH2 domain. Subsequent 
phosphorylation of SLP-76 Y173 occurs (possibly by ITK) creating a putative binding 
site for PLCγ1 SH2C.  Additional protein-protein associations involving Nck, Vav, LAT 
and GADS occur and are included here for context. (b) Binding of PLCγ1 SH2C to SLP-
76 pY173 would open the autoinhibited form of PLCγ1, revealing the kinase docking site 
on PLCγ1 SH2C and priming Y783 for phosphorylation by ITK.  (c) Phosphorylated 
pY783 could compete in an intramolecular fashion with SLP-76 pY173 for the PLCγ1 
SH2C binding pocket disengaging the SH2C with catalytic core and  displacing activated 
PLCγ1 from SLP-76 and creating an open pY173 binding site for priming another 
molecule of PLCγ1.  
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Abstract 
Pleckstrin homology (PH) domains are well known as phospholipid binding 
modules yet many PH domains across the proteome do not exhibit affinity for lipids 
suggesting that PH domain function extends beyond lipid recognition. In the current 
work, we characterize a protein binding function for the PH domain of Interleukin-2-
inducible tyrosine kinase (ITK), an immune cell specific signaling protein that belongs to 
the TEC family of non-receptor tyrosine kinases. Its N-terminal Pleckstrin homology 
(PH) domain is a well characterized lipid-binding module that localizes ITK to the 
membrane via phosphatidylinositol (3,4,5)-trisphosphate (PIP3) binding. Using a 
combination of NMR spectroscopy and mutagenesis, we have mapped an autoregulatory 
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protein interaction site on the ITK PH domain that makes direct contact with the catalytic 
kinase domain of ITK inhibiting the phospho-transfer reaction. Moreover, we have 
elucidated an important interplay between lipid binding by the ITK PH domain and the 
stability of the autoinhibitory complex formed by full length ITK. The ITK activation 
loop in the kinase domain becomes accessible to phosphorylation to the exogenous kinase 
LCK upon binding of the ITK PH domain to PIP3. By clarifying the allosteric role of the 
ITK PH domain in controlling ITK function we have expanded the functional repertoire 
of the PH domain generally and opened the door to alternative strategies to target this 
specific kinase in the context of immune cell signaling. 
 
Introduction 
Protein kinase activity is tightly regulated before, during and after cellular 
signaling events(1). The molecular mechanisms responsible for controlling kinase 
catalytic activity are varied and can depend on the nature of the non-catalytic domains 
within a particular kinase family. For example, biochemical data and high resolution 
crystal structures revealed the regulatory role of the SRC Homology 2 and SRC 
Homology 3 (SH2 and SH3) domains within the SRC kinases (the largest family of non-
receptor tyrosine kinases)(2). In the autoinhibited SRC kinase, these regulatory modules 
pack against the kinase domain in a manner that stabilizes the inactive conformation of 
the catalytic domain(3). Mutations, small molecules or peptides that displace the SH2 
and/or SH3 domains from the kinase domain allow the catalytic domain to sample the 
active conformation leading to efficient phosphorylation of substrates. 
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The TEC kinases (ITK, BTK, TEC, BMX and TXK) are the second largest family 
of non-receptor tyrosine kinases and serve important signaling roles in hematopoietic 
cells during development as well as during activation of mature lymphocytes(4, 5). 
Dysregulation of TEC family members are associated with immunodeficiencies and 
malignancies(6, 7) and so a better understanding of the regulatory machinery of these 
kinases will aid therapeutic developments. A simple extrapolation of the SRC regulatory 
mechanism to the TEC family has not been possible, in part due to the presence of a 
Pleckstrin Homology (PH) domain and the fact that the SRC regulatory tail is absent 
from the TEC kinase family. PH domains are well known lipid-binding modules that 
exhibit specific binding to a range of phosphatidylinositol molecules(8-12). The TEC 
family PH domains bind specifically to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) 
that is transiently produced at the plasma membrane upon antigen receptor activation(13). 
PH domain mediated lipid binding co-localizes the TEC family kinases with the requisite 
adaptor proteins and substrate. 
 
The PH domain of Interleukin-2 inducible tyrosine kinase (ITK) also appears to 
play an important regulatory role in controlling ITK catalytic activity. We have 
previously reported biochemical data that show a significant increase in turnover number 
upon deletion of the N-terminal PH domain of ITK(14). More recently, crystal structures 
of a tethered fragment of Bruton’s tyrosine kinase (BTK) reveal contacts between the 
BTK PH and kinase domains(15). For the non-TEC family kinase, AKT, the regulatory 
role of the PH domain has also become clear through crystallography(16). 
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The full length T cell specific TEC kinase ITK has so far eluded crystallization 
and so we set out to characterize the regulatory role of the ITK PH domain in detail using 
a range of biochemical approaches and solution NMR spectroscopy. Our findings suggest 
that the ITK PH domain contacts the ITK kinase domain directly and exerts an inhibitory 
effect on ITK catalytic activity. We identify a specific surface of the ITK PH domain that 
mediates contacts with the ITK kinase domain and show that mutation of this region of 
the N-terminal PH domain activates ITK kinase activity. The soluble head group of PIP3, 
inositol (1,3,4,5)-tetrakisphosphate (IP4), competes with the regulatory interaction 
between ITK PH and kinase domains consistent with the long standing observation that 
PIP3 production contributes to ITK activation in the activated T cell. Moreover, we find 
that PIP3 containing liposomes activate full length ITK but not an ITK fragment that 
lacks the PH domain. Finally, we show that phospholipid engagement of the ITK PH 
domain exposes the activation loop tyrosine in the ITK kinase domain making it more 
accessible to phosphorylation by the SRC family kinase LCK. The negative regulatory 
interface we have identified on the ITK PH domain overlaps with the previously reported 
Ca2+/Calmodulin (CaM) binding site on ITK, consistent with the observation that 
Ca2+/CaM amplifies ITK signaling(17). The findings reported here provide further insight 
into the expanding repertoire of the PH domain beyond lipid recognition and sets the 
stage for targeting this newly described allosteric mechanism in developing therapeutic 
approaches that complement more traditional ATP inhibitors that bind to the kinase 
active site. 
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Materials and Methods 
Constructs. Baculoviral constructs encoding FLAG-tagged full length ITK (WT 
and K390R) and SH3-SH2-kinase (K390R) fragment (P171-L619) of ITK has been 
described elsewhere(14). Similarly, bacterially expressed construct of His6-GB1 tagged 
ITK PHTH (C96E/T110I) domain has been described previously(18). The baculoviral 
construct of ITK kinase domain was produced using the Gateway cloning system 
(Invitrogen). Briefly, His6 tagged mouse ITK kinase domain (residues 356-619) was 
PCR amplified and cloned into pENTR/D-TOPO vector (Invitrogen). The pENTR/D-
TOPO vector was then recombined with BaculoDirect C-Term Linear DNA (Invitrogen) 
using LR Clonase II (Invitrogen). The recombined linear DNA was then transfected into 
Sf9 cells using Cellfectin II reagent (Invitrogen). Baculovirus was selected and amplified 
for three rounds. All the mutations in the ITK PHTH domain and full length ITK were 
introduced by site directed mutagenesis (QuikChange Lightning Site-Directed 
mutagenesis kit, Agilent). N-terminal His6-GB1-tagged BTK PHTHSH3 domain (mouse, 
aa 1-270), or BTK PHTH domain (aa 1-176) were cloned into the pET20b vector (EMD-
Millipore). C-terminally His6-tagged BTK kinase domain (mouse, aa 396-659) and 
linker-kinase domain (mouse, aa 382-659) were cloned into the pET28a vector (EMD-
Millipore). In addition, both the BTK kinase domain and the BTK linker kinase domain 
constructs had a Y617P mutation which enabled soluble expression in bacteria. The 
mouse LCK kinase domain (aa Q230-P509) construct with an N-terminal 6His-tag in 
pET-28a vector was a kind gift from Dr. John Kuriyan. All constructs were verified by 
sequencing at the Iowa State University DNA Synthesis and Sequencing Facility. 
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Protein purification. Baculovirus production, expression and purification of all 
constructs of FLAG tagged full length ITK (WT and K390R), and FLAG tagged SH3-
SH2-Kinase (K390R) fragment of ITK were carried out as described previously(14) with 
the exception of use of suspension High FiveTM cells (Invitrogen) rather than adherent 
Sf9 cells for protein production. For His6 tagged ITK kinase domain production, High 
FiveTM cells were infected with baculovirus and harvested 48 hours post infection. The 
cell pellet was resuspended in lysis buffer containing 20 mM Tris pH 8, 150 mM NaCl 
and 10 mM Imidazole. The cells were lysed by dounce homogenization and centrifuged 
at 16,000 rpm at 4oC for 1 hour. Glycerol was added to supernatant to a final volume of 
10% and incubated with Ni-NTA resin overnight at 4oC on a rotary mixer. The resin was 
washed 5X with wash buffer containing 20 mM Tris pH 8, 150 mM NaCl, 20 mM 
Imidazole and 10% glycerol. Protein was eluted with elution buffer containing 20 mM 
Tris pH 8, 150 mM NaCl, 250 mM Imidazole and 10% glycerol. Eluted protein was 
passed through HiLoad 26/60 Superdex 75 prep grade column (GE Healthcare Life 
Sciences) pre-equilibrated with buffer 20 mM Tris pH 8, 150 mM NaCl and 10% 
glycerol. The pure protein containing fractions were pooled, concentrated and snap 
frozen and stored at -80oC. His6-GB1 tagged ITK PHTH domain, BTK PHTH domain, 
BTK PHTHSH3 domain, His6-tagged BTK kinase domain or His6-tagged BTK linker 
kinase domain proteins were expressed in Escherichia coli BL21 (DE3) cells and purified 
as described previously with some modifications(14, 18). After elution of protein from 
Ni-NTA column the protein was concentrated to 5 ml and injected onto a HiLoad 26/60 
Superdex 75 prep grade column equilibrated with buffer composed of 50 mM KH2PO4 
pH 7.5, 150 mM NaCl. The eluted protein was then concentrated and subjected to His6-
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GB1 tag cleavage with Factor Xa (Novagen) for 16 hours at room temperature. The 
cleavage reaction was stopped with 1 mM PMSF and loaded onto a Ni NTA column to 
remove His6-GB1 and any uncleaved fusion protein. The flow-through was again passed 
through HiLoad 26/60 Superdex 75 prep grade column pre equilibrated with buffer 
containing Tris pH 8, 150 mM NaCl and 10% glycerol. His6 tagged LCK kinase domain 
was expressed and purified from ArcticExpress cells as described previously(19). The 
LCK protein was eluted with elution buffer containing 20 mM Tris pH 8, 150mM NaCl, 
250mM Imidazole and 10% glycerol. The protein was flash frozen and stored at -80°C. 
 
  PHTH/Kinase domain interaction assay. Purified ITK His6-GB1 PHTH domain 
(2 µM or 4 µM) was immobilized on 20 µL (50% slurry) IgG Sepharose beads (GE 
Healthcare) and was incubated with purified His6-tagged ITK kinase domain (4 µM) in 
buffer containing 20 mM Tris pH 8, 150 mM NaCl and 10% glycerol at 4°C overnight. 
The samples were washed 5 times in the same buffer, suspended in 2X SDS loading 
buffer and boiled. Samples were run on a 12% SDS-PAGE gel for 120 minutes at 180 
volts and transferred onto a PVDF membrane and western blotted with anti His6 antibody 
(Millipore). For pull down assays involving various soluble inositol phosphates (Echelon 
Biosciences and Cayman chemicals), purified ITK His6-GB1 PHTH (2 µM) was 
incubated with specified inositol phosphates for 20 minutes before adding His6-tagged 
ITK kinase domain.  
 
NMR spectroscopy. NMR spectra for ITK PHTH domain in NMR buffer (50mM 
HEPES pH 8, 150mM NaCl, 10% glycerol) was obtained on a Bruker AVII 700 
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spectrometer with a 5 mm HCN z-gradient cryoprobe operating at 1H frequency 700.13 
MHz with sample temperature of 298K. NMR titration was carried out by collecting 1H-
15N HSQC spectra of 200 µM 15N labeled ITK PHTH domain with increasing 
concentration of unlabeled ITK kinase domain (0, 26, and 50 µM). Buffer with 10% 
glycerol was necessary to ensure the stability of ITK kinase domain. NMRviewJ(20) was 
used for NMR spectra visualization and analysis.  
 
In vitro phosphorylation assay. 150 nM full length ITK wild type and mutants 
(K48D/R49D, V28E/F30Y) and 1µM PLCγ1 SH2C-linker substrate(21) were incubated 
in an in vitro kinase assay buffer composed of 50 mM HEPES pH 7, 10 mM MgCl2, 1 
mM DTT, 1 mg/ml BSA, 1 mM Pefabloc, and 200 µM ATP for various time points (0, 
30, 60 and 120 minutes) at room temperature. The samples were boiled for 5 minutes, 
separated by SDS-PAGE and transferred into a PVDF membrane. The membranes were 
blotted with anti-BTK pY551 (BD Biosciences) to detect pY511 levels in ITK. Anti-BTK 
pY511 recognizes the Y511 phosphorylated form of ITK. Anti-ITK (2F12, Thermo 
Scientific) and PLCγ1 pY783 (EMD Millipore) monoclonal antibody were used to detect 
total enzyme levels and PLCγ1 pY783 levels, respectively. Total PLCγ1 level was probed 
by Coomassie staining. In kinase assays to test the effect of inositol lipids, ITK enzyme 
was pre incubated with soluble inositol phosphates or PIP3 liposomes for ten minutes 
before starting the reaction. 
 For the ITK loop accessibility kinase assay using active LCK kinase domain, 1 
µM full length ITK (K390R) or ITK SH3-SH2-kinase (K390R) fragment were incubated 
with 100 µM liposomes for 10 minutes prior to the addition of 200 nM LCK kinase 
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domain to start the reaction. The reaction was carried out for 5 minutes at room 
temperature. The pY511 level was detected as described above. Total ITK and ITK SH3-
SH2-Kinase level was detected with an anti-FLAG antibody (Sigma) and total LCK level 
was detected with anti His6 antibody (Millipore). 
 
Liposome preparation. 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-
dioleol-sn-glycero-3-[phospho-L-serine] (DOPS) and 1-stearoyl-2-arachidonoyl-sn-
glycero-3[phosphoinsositol-3,4,5-triphosphate] (PIP3) (Avanti polar lipids) were 
separately dissolved in chloroform. For liposomes containing PIP3, all three lipids were 
mixed in 75:10:5 molar ratio (DOPC:DOPS:PIP3). For control liposome (without PIP3) 
DOPC and DOPS were mixed in 79:21 molar ratio (DOPC:DOPS). After mixing, 
chloroform was evaporated by gentle flow of nitrogen into the test tube containing the 
lipid mixture. The lipid mixture was then dried overnight at room temperature in a 
vacuum desiccator. The dried lipid films were hydrated for one hour at room temperature 
with buffer containing 50 mM HEPES (pH 7) such that the final liposome concentration 
is 12 mM. The hydrated lipid films were then subjected to five freeze thaw cycles using 
liquid nitrogen and a 37°C water bath. Unilamellar liposomes were created using the mini 
extrusion set (Avanti polar lipids) by passing through a 100 nM filter (Whatman). 
Liposomes were then stored at 4°C and used within 48 hours. 
 
CD spectroscopy. CD spectra of 5 µM ITK PHTH wild type and mutants were 
acquired on a Jasco J-710 in the far UV region (190-240 nm). The samples were prepared 
in buffer containing 10 mM NaH2PO4 (pH 7.4). CD spectra were obtained at a scanning 
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rate of 100 nm/min with a spectral bandwidth of 2 nm and response time of 1 s. All CD 
spectra are the average of two scans and were converted from mdegree into molar residue 
ellipticity (deg cm2 dmol-1). 
 
 
Results 
 
Full length ITK kinase consists of three regulatory domains: PHTH, SH3, and 
SH2 that are positioned N-terminal to the catalytic kinase domain (Fig. 1a). It should be 
noted here that the TH (or TEC Homology) region of the TEC family kinases is 
considered an extension of the PH fold and so throughout this work we are using the 
larger ITK fragment that contains both PH and TH regions (ITK PHTH). Based on 
previous biochemical findings that suggest a role for the PHTH domain in controlling 
kinase activity(14), we set out to better understand how the ITK PHTH region exerts 
control over ITK mediated phosphorylation. We first expressed and purified His6-GB1 
fused ITK PHTH domain and a separate His6 tagged ITK kinase domain (Fig. 1a). 
 
The purified ITK N-terminal fragment, His6-GB1-PHTH (Fig. 1a) was 
immobilized using IgG sepharose and incubated with the ITK kinase domain. Following 
extensive washing of the sepharose beads, we find that the ITK kinase domain binds to 
the ITK PHTH fragment in a concentration dependent manner (Fig. 1b, lanes 7,8). 
Interestingly, the analogous interaction is not detected in similar experiments with the 
BTK PHTH and kinase domains (Fig. 1c,d, lanes 6,9). A large loop insertion in the BTK 
PHTH domain makes it similar in size to the BTK kinase domain and so we assessed the 
possibility of a direct interaction using the larger BTK His6-GB1-PHTH-SH3 fragment 
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and the BTK His6-Kinase as well as the BTK linker-kinase domain (Fig. 1c,d, lanes 
7,10). No interaction is detected between these N-terminal and C-terminal domains of 
BTK (Fig. 1d) under the same conditions used to detect the ITK PHTH/kinase interaction 
(Fig. 1b). These data therefore suggest that ITK PHTH interacts in trans with the ITK 
kinase domain and a corresponding in trans interaction between the BTK PHTH and 
kinase domains is not detected in the assay. 
 
To further characterize the ITK PHTH/kinase interaction we expressed and 
purified 15N-labeled ITK PHTH for NMR spectroscopy. Using previously published 
assignments for an ITK PHTH variant harboring two mutations ((C96E/T110I) that 
improve expression and solubility(17, 18), we titrated unlabeled ITK kinase domain into 
the labeled ITK PHTH domain and acquired 1H-15N HSQC spectra at each point of the 
titration (Fig. 2a-c). Many of the PHTH amide NH resonances in the HSQC spectrum do 
not change throughout the course of the titration (Fig. 2b,c). A subset of ITK PHTH 
resonances, however, show selective disappearance as the concentration of ITK kinase 
domain is increased (Fig. 2b,c). Mapping these spectral changes onto a structural model 
of ITK PHTH shows the residues that are affected by binding of ITK kinase domain are 
primarily located in two regions: across β-strands 2-4 of the PH domain and one side of 
the long α-helix of the PH domain fold (Fig. 2d). 
 
NMR spectral changes are sensitive to small changes in local environment and 
often map a surface or region that is larger than the actual interface between two proteins 
in a complex. We therefore used mutagenesis to refine the binding site on the ITK PHTH 
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domain that mediates the interaction with the ITK kinase domain. Based on NMR 
spectral changes, we first mutated residues within the beta strand region (β2-β4) as well 
as residues on the β3-β4 loop. Mutations were chosen to directly probe residues for which 
NMR spectral changes were observed (Fig. 2d) and to assess other residues in this beta-
strand region that have surface exposed sidechains but lacked an observable spectral 
change either due to intramolecular hydrogen bonding, adverse conformational dynamics 
and/or lack of assignment. Specific amino acid mutations were based on either the 
corresponding residue in BTK, a charge reversal or mutation to alanine. The extent of 
interaction of wild type ITK PHTH and each PHTH mutant with the ITK kinase domain 
was assessed using the same pull down assay described in Figure 1 (Fig. 3a,b). A greater 
than 50% decrease in binding of the ITK kinase domain to ITK PHTH was observed 
upon mutation of four residues: (Fig. 3b; V28, F30, K48, and R49). Mutation of two 
additional residues, L51D and E56A, causes a 50% decrease in binding between the ITK 
kinase and PHTH domains (Fig. 3b). To further probe the ITK PHTH surface, we 
mutated additional surface residues across the entire ITK PHTH domain (including 
surface exposed side chains on the α-helix) and find only small changes in ITK 
kinase/PHTH binding (Fig. 3c,d) suggesting that these additional sidechains do not 
substantially contribute to the interaction between the two domains. 
 
Mapping the mutagenesis results onto a model of the ITK PHTH domain shows 
that the residues that mediate binding of the ITK kinase domain to ITK PHTH cluster in 
one region of the PHTH domain and those residues that do not contribute to the 
interaction based on mutagenesis data are outside of this newly defined binding surface 
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(Fig. 3e-g). The secondary structural elements within PHTH involved in mediating the 
PHTH/kinase interaction include the beta strands β2 and β4 and the β3-β4 loop (Fig. 
3e,f). 
 
 Our previous biochemical work assessing the activity of ITK deletions(14) 
suggested that the ITK PHTH region inhibits ITK kinase domain activity.  Having 
mapped the surface on the ITK PHTH domain responsible for the interaction with the 
ITK kinase domain, we next introduced specific PHTH domain mutations into full length 
ITK and measured both ITK activation loop autophosphorylation (pY511) and 
phosphorylation of the ITK substrate PLCγ1 (pY783) to determine the extent to which 
specific PHTH domain residues affect ITK catalytic activity. Mutation of two pairs of 
PHTH domain residues, K48/R49 and V28/F30, caused the largest decrease in the ITK 
PHTH/kinase domain interaction (Fig. 3a,b) and so these residues were mutated in full 
length ITK. Using CD spectroscopy, we first established that these mutations do not alter 
the overall fold of the PHTH domain but retain the secondary structure of the wild type 
sequence (Fig. 4a). The kinase activity of full length wild type ITK was then compared to 
the full length double mutants, ITK K48D/R49D and ITK V28E/F30Y, ensuring that 
each enzyme is not phosphorylated on the activation loop tyrosine (Y511) at the 
beginning of the assay (Fig. 4b-d). Both sets of mutations in the PHTH domain affect 
ITK catalytic activity; activation loop phosphorylation levels (pY511) and 
phosphorylation of exogenous PLCγ1 are increased compared to wild type ITK (Fig. 4b-
d). While both sets of mutations increase ITK activity, mutation of K48/R49, at the center 
of the newly defined binding surface on the ITK PHTH domain (Fig. 3e), has a greater 
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effect on the kinase activity of full length ITK than does the more peripheral V28E/F30Y 
mutation. Thus, mutations in the ITK PHTH domain that disrupt the interaction with the 
kinase domain appear to reduce autoinhibition and increase catalytic function of the ITK 
kinase domain. 
 
In the context of cell signaling, the PHTH domain of ITK binds to 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) at the membrane via a conserved 
binding pocket. The lipid binding pocket on ITK PHTH is adjacent to the cluster of 
amino acids we have identified here that mediate an autoinhibtory interaction with the 
ITK kinase domain (Fig. 5a). In fact, R29, which is located between V28 and F30 in the 
ITK PHTH domain, is the conserved arginine that mediates binding to the negatively 
charged lipid head group. Given the juxtaposition of this lipid binding residue between 
two residues that mediate the autoinhibitory PHTH/kinase interaction, we decided to 
avoid mutagenesis and instead test whether binding of the soluble head group of PIP3, 
inositol (1,3,4,5)-tetrakisphosphate (IP(1,3,4,5)P4), affects the interaction between ITK 
PHTH and ITK kinase domain. In this assay we compare the interaction between ITK 
PHTH and ITK kinase domain in the presence of increasing concentration of 
IP(1,3,4,5)P4 and a control inositol (1,3,4,6)-tetrakisphosphate (IP(1,3,4,6)P4 ) (Fig. 5b,c). 
The amount of ITK kinase domain that associates with ITK PHTH decreases in the 
presence of increasing inositol 1,3,4,5 tetrakisphosphate ligand concentration but not the 
inositol 1,3,4,6 tetrakisphosphate regioisomer (Fig. 5b,c). To further test specificity we 
examined a panel of inositol phosphates and find that the inositol tertakisphosphate (IP4), 
specifically, inositol (1,3,4,5)-tetrakisphosphate is the only soluble lipid among eleven 
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tested that disrupts the ITK PHTH/kinase domain interaction to greater than 50% (Fig. 
5d,e (lane 8)). This suggests that the ITK PHTH/kinase domain interaction is mutually 
exclusive with lipid binding to the ITK PHTH domain and is specific to the soluble lipid 
head group of PIP3. 
 
Since inositol (1,3,4,5)-tetrakisphosphate specifically interferes with the ITK 
PH/kinase interaction we next examined the effect of IP4 on ITK kinase activity. Using 
the same kinase assay described in Figure 4b, ITK activation loop phosphorylation levels 
(pY511) were monitored in the presence of increasing concentration of IP(1,3,4,5)P4 or 
the regioisomeric control compound IP(1,3,4,6)P4. ITK activation loop phosphorylation 
decreases with increasing IP4, whether the isomer corresponding to the soluble head 
group of the physiologically relevant PIP3 (IP(1,3,4,5)P4) or the regioisomer IP(1,3,4,6)P4 
is used in the assay (Fig. 6a,b). Previous findings showed no change in ITK mediated in 
vitro phosphorylation of a non-physiological peptide substrate(22) and so together these 
results suggest that either IP4 by itself does not directly activate ITK in spite of 
interfering with the regulatory PHTH/Kinase interaction, or at the concentrations required 
to disrupt the PHTH/kinase interaction, IP4 is incompatible with the in vitro kinase assay 
causing non-specific inhibition of ITK activity. The observation that the regioisomeric 
IP4 compound decreases ITK activation loop phosphorylation to the same extent as the 
physiologically relevant IP4 (IP(1,3,4,5)P4) (Fig. 6b) but does not disrupt the ITK 
PHTH/kinase interaction (Fig. 5c) supports the conclusion that the in vitro ITK kinase 
assay is not a reliable measure of the effect of IP4 on ITK function. 
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In an effort to circumvent the non-specific kinase inhibition caused by soluble IP4, 
we expanded the ITK in vitro kinase assay to examine the effect of the ITK PHTH 
domain target, PIP3; the plasma membrane bound phospholipid produced by 
phosphoinositide 3-kinase following T cell receptor activation(23). ITK activation loop 
phosphorylation levels (pY511) were monitored in the presence of PIP3 containing 
liposomes as well as control liposomes that lack PIP3. Unlike the equivocal effects of IP4 
on ITK activity, PIP3 activates ITK as measured by phosphorylation on the activation 
loop tyrosine Y511 (Fig. 6c, lane 2, 6d) whereas control liposomes do not enhance 
activation loop phosphorylation (Fig. 6c, lane 3, 6d). This result is consistent with 
binding of the PIP3 headgroup in a manner that competes with an autoregulatory 
interaction mediated by the ITK PHTH domain (Fig. 5a). 
 
To gain additional insight into precisely how PIP3 leads to increased 
phosphorylation on the ITK activation loop, we next carried out a combined kinase assay 
that makes use of kinase inactive full length ITK (K390R), the inactive ITK fragment 
lacking the PHTH domain (ITK SH3-SH2-Kinase (K390R)) and active LCK kinase 
domain, the SRC family kinase that is responsible for phosphorylation of ITK Y511 in 
activated T cells(24) (Fig. 7a). The catalytically inactive full length ITK (K390R) and 
ITK SH3-SH2-Kinase (K390R) are used in this assay to ensure that phosphorylation on 
ITK Y511 is solely due to LCK activity and not due to intrinsic ITK activity. Thus, the 
extent to which ITK Y511 is phosphorylated by exogenous LCK reveals the accessibility 
of the ITK activation loop under different conditions(25). Both full length ITK (K390R) 
and the ITK SH3-SH2-Kinase (K390R) fragment are subjected to phosphorylation by 
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active LCK in the presence and absence of PIP3. In the absence of PIP3 (either no 
liposomes or control liposomes (PC/PS) that do not contain PIP3) we find the ITK SH3-
SH2-Kinase (K390R) fragment is phosphorylated on Y511 to a greater extent than full 
length ITK (K390R) (Fig. 7b,c lanes 3 & 4 and 7 & 8) suggesting that the PHTH domain 
reduces accessibility of the ITK activation loop to LCK. For full length ITK (K390R) in 
the presence of PIP3 containing liposomes (PC/PS/PIP3), LCK dependent 
phosphorylation of the ITK activation loop tyrosine (pY511) is higher than full length 
ITK (K390R) in the absence of liposomes or in the presence of control liposomes (Fig. 7 
b,c lane 6 versus 2, 4 & 8). In contrast, LCK mediated phosphorylation of the activation 
loop tyrosine Y511 in the ITK SH3-SH2-Kinase fragment that lacks PHTH is unaffected 
by the presence or absence of PIP3 (Fig. 7b,c lanes 3,5,7). These observations suggest 
that binding of PIP3 to the ITK PHTH domain ‘activates’ ITK by unmasking of the ITK 
activation loop making it more accessible to phosphorylation by LCK. 
 
Discussion 
 
The findings reported here support an autoregulatory role for the PHTH region in 
controlling the catalytic activity of ITK. The role of the PHTH domain in ITK regulation 
has been hinted at in previous deletion studies(14) but not previously dissected at the 
molecular level. In the context of the full length ITK enzyme, a specific surface on the 
PHTH domain encompassing the β3-β4 loop of the PH fold mediates a direct interaction 
with the ITK kinase domain resulting in diminished ITK catalytic activity. Mutation of 
ITK PHTH residues at this interface leads to activation of the remote catalytic domain in 
the full length ITK enzyme. 
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A structural model of the autoinhibited form of the related TEC family kinase, 
BTK, has recently been reported(15). Consistent with our observation that the BTK 
PHTH and BTK kinase domains do not interact in trans (Fig. 1d), crystallographic 
analysis of the BTK PHTH/kinase interaction required a tethered BTK PHTH-Kinase 
construct, which yielded a structure defining a PHTH/kinase interface centered on the 
base of the PH domain α-helix (Fig. 8a). R133 and Y134 in the BTK PH domain mediate 
primary sidechain contacts between BTK PH and kinase domains in the tethered BTK 
crystal structure(15) yet NMR resonances for the corresponding ITK residues, R111 and 
N112, as well as that of the neighboring residue N113, are unaffected by addition of 
unlabeled ITK kinase domain (Fig. 2b,c). Moreover, mutation of ITK R111 to glutamate 
does not affect the ITK PHTH/kinase interaction (Fig. 3d). These findings support the 
conclusion that the PHTH/kinase interface observed in the crystal structure of the 
tethered BTK PHTH-kinase construct is not the interface that mediates the autoregulatory 
ITK PHTH/kinase contact. Instead, ITK residues in the β3-β4 loop of the PHTH domain 
and not those on the α-helix are primarily responsible for mediating the ITK 
PHTH/kinase autoinhibitory interaction (Fig. 8a). 
 
Typically protein kinases belonging to the same family are regulated by related 
mechanisms and yet our data describing ITK autoinhibition diverge from the available 
structural model of BTK. If autoinhibition of these related kinases are in fact mediated by 
a shared mechanism, it is possible that the alternative PHTH/kinase interaction evident in 
BTK(15) (Fig. 8a) might represent an intermediate state between fully autoinhibited and 
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active kinase that was captured as a result of tethering the BTK PHTH and kinase 
domains. Indeed, mutation of the BTK β3-β4 loop residues that correspond to the ITK 
PHTH domain surface we have defined here (BTK R49E and K52E (K48 and L51 in 
ITK)) was shown to activate BTK catalytic activity(15). Since these β3-β4 loop residues 
of the BTK PHTH domain are not located at the PHTH/kinase interface in the tethered 
BTK structural model, the authors of that work suggested that mutations in the BTK β3-
β4 loop might alleviate electrostatic repulsion allowing transient dimerization (and hence 
autophosphorylation) to occur more favorably. Our data clearly support an ITK inhibitory 
contact between PHTH and kinase domains and it remains to be determined whether or 
not ITK is also regulated by PHTH domain mediated dimerization. By the same token, it 
is also possible that, like ITK, the β3-β4 loop of the BTK PH domain might mediate 
important autoinhibitory contacts with the BTK kinase domain not captured in the crystal 
structure of the tethered domains. 
 
Regardless of the exact details of autoinhibition of ITK and BTK, differences do 
persist within this kinase family since we find that the ITK PHTH/kinase interaction can 
be readily detected intermolecularly while the BTK PHTH/kinase interaction cannot (Fig. 
1). This observation suggests that the intramolecular regulatory interaction (regardless of 
details) is stronger in ITK than BTK, an idea that is consistent with earlier work 
suggesting that B cell proteins such as BTK and SYK are more easily activated than their 
T cell counterparts, ITK and ZAP-70(25, 26). The reason for differences in regulation of 
ITK and BTK may be related to the notion that, compared to B cells, T cell activation 
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needs to be under stricter control given the deleterious effects of over production of 
inflammatory cytokines(25). 
 
The ITK PHTH binding residues in and around the β3-β4 loop are close to the 
binding site of the PIP3 phospholipid head group (Fig. 8a) consistent with the observation 
that binding of the soluble head group of the PIP3 ligand, IP(1,3,4,5)P4, selectively 
disrupts the ITK PHTH/kinase interaction (Fig. 5). This finding may also be related to 
earlier observations that IP(1,3,4,5)P4 itself promotes activation of ITK in T 
lymphocytes(22) and so IP(1,3,4,5)P4 might, at least in part, pry open the autoinhibited 
form of ITK. However, the results of in vitro assays in the presence of inositol 
tetrakisphosphates suggest difficulty in directly measuring the effect of IP4 on ITK kinase 
activity (Fig. 6a,b). It should also be noted that the autoinhibitory region of the ITK PH 
domain that we have identified here partially overlaps with a peripheral binding site 
identified on the BTK PH domain that binds IP6(15). IP6 binding to the BTK PH domain 
putatively stabilizes transient dimerization and subsequent BTK autophosphorylation(15). 
Yet, as the authors in that work note, the peripheral BTK IP6 binding site is not conserved 
in ITK and so an IP6 regulatory role for ITK seems unlikely. 
 
The well characterized physiological ligand of the ITK PHTH domain, PIP3, is a 
membrane bound phospholigand produced upon T cell activation. Using PIP3 containing 
liposomes we find that phospholigand binding to the ITK PHTH domain leads to ITK 
activation by enhancing LCK mediated phosphorylation of the ITK activation loop 
tyrosine Y511 (Fig. 7). The data suggest that engagement of the ITK PHTH with 
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phospholipid ligand leads to release of the autoinhibitory PHTH/kinase contact (opening 
of the compact domain arrangement suggested in the BTK crystal structure) revealing the 
ITK activation loop tyrosine (ITK Y511) to the LCK active site (Fig. 8b). 
 
 Inspecting the electrostatic surface of the ITK kinase domain shows that there is a 
large acidic patch extending from the N-lobe over the activation loop that might provide a 
complementary binding surface for the positively charged amino acids in the ITK PHTH 
β3-β4 loop (Fig. 8c). Further structural work will definitively determine whether this 
acidic surface on the ITK kinase domain serves as the binding interface with the ITK 
PHTH domain in the autoinhibitory conformation. Like ITK, the BTK kinase domain 
shares the large negatively charged surface (Fig. 8d) yet this is not the surface contacted 
by the BTK PHTH domain in the structural model that emerged from tethering the two 
domains(15). The serine/threonine kinase belonging to the AGC superfamily, AKT, is 
also regulated by its PH domain and a crystal structure of that regulatory complex shows 
the AKT PH domain occludes the kinase active site by contacting the corresponding 
region of the AKT kinase domain that extends from the N-lobe across part of the 
activation loop(16). Certainly, a similar autoinhibitory mechanism for the TEC family 
kinases ITK and BTK that sterically precludes activation loop phosphorylation seems 
plausible and is supported by the ITK/LCK loop accessibility assay described here (Fig. 
7). 
 
The ITK PHTH β3-β4 loop has also been previously implicated in binding the 
calcium binding protein, Calmodulin(17). Binding of Ca2+/Calmodulin to the ITK PHTH 
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domain (via β3-β4 loop residues) was shown to result in sustained ITK activation and 
potentiated calcium signaling in T cells. Based on the negative regulatory role we have 
now demonstrated for this region of ITK PHTH, it is possible that one of the 
consequences of Ca2+/Calmodulin binding to ITK is to maintain an open, active state and 
prevent formation of the autoinhibitory state. Along these lines, it is interesting to note 
that the COSMIC (catalogue of somatic mutations in cancer) database lists several 
mutations in ITK that span the PHTH interface responsible for binding to the ITK kinase 
domain (Fig. 8e). It is possible that these mutations activate ITK kinase activity in much 
the same way that the targeted mutations studied here abolish the autoregulatory 
PHTH/kinase interaction (Fig. 3) and increase ITK mediated phosphorylation of PLCγ1 
(Fig. 4). Similar oncogenic activation via PH domain mutations has been reported for 
AKT(27). 
 
It is becoming increasingly clear that Pleckstrin Homology domains target non-
lipid binding partners in addition to membrane-bound phospholipids. A recent review by 
Huang and co-workers(28) highlights the varied roles of the PH domain in lymphocyte 
signaling as well as the regulatory role of the PH domain in non-lymphocytic proteins 
generally. In one example, the DH-PH domain module of Dbs, a Cdc42 specific Guanine 
Exchange Factor, contacts Cdc42 via the β3-β4 loop of the Dbs PH domain(29). In 
another example, the guanine nucleotide exchange factor P-Rex2 recognizes its substrate 
G protein via the β3-β4 loop region of the PH domain(30). With our observations of a 
critical role for the same β3-β4 loop of ITK PHTH in binding the ITK kinase domain as 
well as Ca2+/Calmodulin(17), it is possible that this region of the PH fold may serve as a 
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general protein recognition motif. It is noteworthy that binding mediated by the β3-β4 
loop region of the PH domain seems sensitive to phospholipid binding at a nearby site 
suggesting significant interplay between lipid and protein recognition by this common 
signaling domain. The growing examples of PH domain mediated regulation also suggest 
that the specific protein interactions mediated by the PH fold are potential targets for 
allosteric regulation of signaling molecules via the activity of small molecules. Indeed, 
targeting AKT in this manner has already been demonstrated providing proof of principle 
for other systems such as the TEC family kinases. 
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Figure Captions 
 
Figure 1. The ITK PHTH domain interacts with the ITK kinase domain in trans. (a) 
Domain constructs of ITK used in this study. Full length ITK is shown above the His6-
GB1-tagged PHTH domain fragment of ITK (residues 1-154) and the His6-tagged Kinase 
domain fragment (residues 356-619). (b) Coomassie gel showing ITK kinase domain (4 
µM) associates with ITK PHTH domain (2 and 4 µM in lanes 7 and 8, respectively) 
immobilized on IgG sepharose beads. Lanes 1 shows the ITK kinase domain alone does 
not associate with IgG sepharose, lanes 2, 3 and 4 are loading controls. Lane 5 shows the 
ITK kinase domain and asterisks show the IgG heavy and light chains. Lane 6 shows that 
the ITK kinase domain does not associate with IgG sepharose bound His6-GB1 that lacks 
ITK PHTH. (c) Domain constructs of BTK used in this study. Full length BTK is shown 
above the His6-GB1-tagged PHTHSH3 (residues 1-270), the His6-GB1-tagged PHTH 
(residues 1-176) and the His6-tagged Kinase domain fragments of BTK (residues 396-
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659 (Kinase domain) and residues 382-659 (Linker-Kinase domain)). (d) Coomassie gel 
showing that neither the BTK kinase domain (1 µM) or the BTK linker-kinase domain (1 
µM) associates in this assay with either the BTK PHTH domain (2 µM) or the larger 
BTK PHTHSH3 construct (2 µM) immobilized on IgG sepharose beads (lanes 6,7,9 and 
10). Protein alone loading controls are shown on the left side of the gel. As in (b) 
asterisks indicate IgG heavy and light chains. 
 
Figure 2. NMR mapping of the ITK PHTH regulatory interface. (a) [15N,1H]- HSQC 
spectrum of uniformly 15N-labeled ITK PHTH domain. (b,c) Addition of unlabeled ITK 
kinase domain to uniformly 15N-labeled ITK PHTH domain results in significant 
broadening and in some cases chemical shift changes of selected peaks (boxed) in the 
overlay of [15N, 1H] HSQC spectra acquired during the titration. A large subset of ITK 
PHTH resonances do not change over the course of the titration. ITK R111, N112 and 
N113 (corresponding to R133, Y134 and N135 in BTK), do not change during the 
titration (circled). Black spectrum corresponds to ITK PHTH alone (200 µM), cyan 
spectrum acquired after addition of 26 µM unlabeled ITK kinase domain and red 
spectrum acquired after addition of 50 µM unlabeled ITK kinase domain. (d) 
Computational model of ITK PHTH based on crystal structures of the corresponding 
BTK domain fragment (PDB IDs: 1BTK and 1B55); threading was performed using I-
TASSER(31).	   ITK PHTH residues for which spectral changes were observed in the 
NMR data shown in (a-c) are shown in red and labeled. The residues located on β-strands 
2-4 are circled and those on the α-helix are boxed. All structural figures were made using 
PyMol(8). 
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Figure 3.  NMR based mutagenesis refines the surface of the ITK PHTH domain that 
contacts the ITK kinase domain.  (a,c) Anti-His6 blots showing ITK kinase domain 
(4µM) associates to different extents with wild type and mutant ITK PHTH domain 
(2µM) that is immobilized on IgG sepharose beads. (b,d) The fraction of ITK kinase 
domain bound to wild type and mutant ITK PHTH domains; bound kinase is normalized 
to His6-GB1 PHTH level in each lane and then compared to wild type (wt). The dotted 
line shows a decrease in ITK PHTH/kinase domain interaction of 50%. Data shown in (a) 
and (c) are representative of three independent experiments. (e,f) The binding surface 
determined from the data in (a) and (c) is mapped onto the ITK PHTH domain 
computational model, labeled and shown in red. The interface residues are located on the 
β4 and β2 strands as well as the β3-β4 loop. Those residues that, upon mutation, do not 
disrupt the ITK PHTH/kinase domain interaction are labeled and shown in cyan. In (f) 
R111 is circled as it corresponds to the BTK residue R133 that is at the interface of the 
tethered BTK PHTH and kinase domains for which a crystal structure was recently 
solved(15). (g) Two views of the ITK PHTH surface residues shown in (e) and (f) where 
red indicates involvement in the ITK PHTH/kinase interaction and cyan corresponds to 
those residues for which mutation does not affect the ITK PHTH/kinase interaction. The 
β3-β4 loop residues that are within the binding site identified here are colored pink but 
were not probed directly by mutagenesis. 
 
Figure 4. Mutation of the ITK PHTH interface residues in full length ITK increases ITK 
catalytic activity. (a) Circular dichroism spectra for wild type ITK PHTH (blue), ITK 
PHTH (K48D/R49D) (green) and ITK PHTH (V28E/F30Y) (red). (b) Kinase assay 
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spanning 0-120 minutes showing ITK activation loop autophosphorylation (pY511) and 
phosphorylation of exogenous PLCγ1 (pY783) for full length, wild type ITK (150 nM) in 
lanes 1-4, full length ITK mutant K48D/R49D (150 nM) in lanes 5-8, and full length ITK 
mutant V28E/F30Y (150 nM) in lanes 9-12. Phosphorylation of ITK Y511 is detected 
using anti-BTK pY551 (labeled Anti pY511 for clarity throughout), PLCγ1 pY783 levels 
are detected using anti-pY783 antibody and total enzyme levels are detected using anti-
ITK antibody. Total PLCγ1 substrate levels (SH2C-linker) are detected using Coomassie 
stain. (c,d) Histogram representation of normalized  pY511 (c) and pY783 (d) levels from 
the ITK kinase assays shown in (b). The intensities of the band corresponding to pY511 
and pY783 were divided by the total ITK enzyme level in each lane. The value of these 
ratios for ITK (K48D/R49D) at time point 120 minutes was set to 1. All other intensity 
ratios are shown relative to this value. Experiments were run in triplicate.  
 
Figure 5. The ITK PHTH/Kinase interaction is selectively disrupted by binding of soluble 
inositol 1,3,4,5-tetrakisphosphate (IP(1,3,4,5)P4). (a) Close up view of the ITK PHTH 
interface residues that mediate contact to the ITK kinase domain (labeled and in red) and 
the adjacent lipid binding site. The computational model of the ITK PHTH domain was 
aligned with the crystal structure of BTK PHTH domain bound to IP(1,3,4,5)P4 (PDB ID: 
1B55). BTK PHTH domain is not shown for clarity. The IP4 head group of PIP3 is shown 
bound to the PHTH domain and positions 1,3,4, and 5 are labeled. The position of the 
conserved arginine that binds IP4 is indicated to show that it sits between two residues 
that mediate contacts to the ITK kinase domain (V28 and F30). (b) Anti-His6 blots 
showing ITK kinase domain (4µM) binding to the ITK PHTH domain (2µM) 
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immobilized on IgG sepharose beads in the presence of soluble inositol 1,3,4,5-
tetrakisphosphate (IP(1,3,4,5)P4) and the regioisomeric IP4, inositol 1,3,4,6-
tetrakisphosphate (IP(1,3,4,6)P4). The first lane shows total ITK kinase domain input 
followed by increasing concentration of IP4 compounds (0-10 µM). (c) Histogram 
representation of the fraction of ITK kinase domain bound to the ITK PHTH domain at 0, 
0.5, 1, 2, 5 and 10 µM IP4 (data for inositol 1,3,4,5-tetrakisphosphate is on the left and 
inositol 1,3,4,6-tetrakisphosphate is on the right). Bound kinase is normalized to His6-
GB1 PHTH level in each lane and then compared to the amount of bound kinase in the 
absence of IP4 (0 µM). (d,e) The same experiment described for panels (b) and (c) is 
carried out for a panel of inositol phosphates. Lane 1 (apo) contains no added inositol 
phosphate and the specific compound used in lanes 2-12 is indicated above the blot in (d). 
The concentration of all inositol phosphates is 5 µM. The IP4 compound that is the 
soluble head group of the PIP3 target of ITK in T cells (inositol 1,3,4,5-tetrakisphosphate) 
is labeled in red. 
 
Figure 6. PIP3 activates ITK catalytic activity. (a) In vitro ITK kinase assay (500 nM 
ITK) in the presence of 1, 10, and 100 µM inositol 1,3,4,5-tetrakisphosphate (lanes 2-4) 
and the regioisomer control inositol 1,3,4,6-tetrakisphosphate (1, 10, and 100 µM, lanes 
5-7). Lane 1 contains no inositol phosphate. ITK activation loop autophosphorylation 
(pY511) is detected at 30 minutes using using anti-BTK pY551 and total enzyme levels 
are detected using anti-ITK antibody. (b) Histogram representation of normalized pY511 
levels from the ITK kinase assays shown in (a). Normalization was done as before in 
Figure 4(c and d), except that the value for ITK in the absence of any phosphoinositol 
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compound was set to1.  Experiments were run in triplicate. (c) In vitro ITK kinase assay 
in solution (lane 1), in the presence of PIP3 containing liposomes (lane 2) and control 
liposomes that lack PIP3 (lane 3). PC indicates 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) and PS is 1,2-dioleol-sn-glycero-3-[phosphor-L-serine] (DOPS). ITK 
concentration, reaction time, and detection of activation loop phosphorylation and total 
enzyme levels are as described for panel (a). (d) Histogram representation of normalized 
pY511 levels from the ITK kinase assays shown in (c). Normalization was carried out as 
in panel b above. Experiments were run in triplicate. 
 
Figure 7. The activation loop in the ITK kinase domain is sterically blocked by the PHTH 
domain in autoinhibted ITK. (a) Domain constructs of ITK and LCK. Full length ITK and 
the fragment lacking the PHTH domain (ITK SH3-SH2-Kinase) are FLAG-tagged at the 
C-termini and the LCK kinase domain carries a His6 tag at the N-terminus. Full length 
ITK and the ITK SH3-SH2-kinase fragment contain the K390R mutation rendering both 
inactive(24) . (b) In vitro LCK kinase assay in solution (lanes 3 and 4), in the presence of 
PIP3 containing liposomes (lanes 5 and 6) and control liposomes that lack PIP3 (lanes 7 
and 8). ITK SH3-SH2-Kinase (K390R) (1 µM, lanes 3,5,7) and full length ITK (K390R) 
(1 µM, lanes 4,6,8) serve as substrates for LCK (200 nM). Lanes 1 and 2 are no enzyme 
(LCK) controls. Phosphorylation of ITK Y511 is detected using anti-BTK pY551 and 
total substrate and enzyme levels are detected using anti-FLAG and anti-His6 antibodies, 
respectively. (c) Histogram representation of normalized pY511 levels from the LCK 
kinase assays shown in (b). Normalization was done as in Figure 4 (c and d) with the 
value for ITK in the absence of liposomes set to 1. Data for the ITK SH3-SH2-Kinase 
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(K390R) substrate is on the left and the full length ITK (K390R) substrate is on the right. 
Experiments were run in triplicate. 
 
Figure 8. The ITK PHTH domain contacts its cognate kinase domain in a manner that 
differs from the current model of autoinhibted BTK. (a) The structure of tethered BTK 
PHTH-Kinase domain (PDB ID: 4Y93) where the ITK PHTH domain has been 
superimposed with the BTK PHTH domain (BTK PHTH not shown for clarity). R133 in 
the BTK PHTH domain makes contact with the BTK kinase domain. R111 is the 
corresponding residue in the ITK PHTH domain but mutation of R111 does not affect the 
ITK PHTH/Kinase interaction. The ITK PHTH interface residues located in and around 
the β3-β4 loop (colored red) are not located at the interface with the kinase domain 
defined in the crystal structure for the tethered BTK domains but are close to the 
IP(1,3,4,5)P4 binding site (circled). (b) left, Model of closed, autoinhibited ITK in a 
resting T cell (arrangement of the SH3 and SH2 domains is based on the BTK crystal 
structure of the SH3-SH2-Kinase fragment (4XI2)). Right, model of an open form of ITK 
(based on SAXS structure of full length BTK(32)  in the presence of membrane anchored 
PIP3 revealing Y511 for phosphorylation by LCK. (c) The ITK kinase domain presents a 
large negatively charged surface that spans the N-lobe and activation loop and may serve 
as a binding site for the positively charged region of ITK PHTH defined in this study. 
The highly basic stretch of residues on the β3-β4 loop are shown and labeled. (d) The 
BTK kinase domain shares the acidic patch across the N-lobe and activation loop. (e) 
Autoinhibitory ITK PHTH surface defined in this study. Residues shown in red are those 
side chains mutated in the current study that have an effect on the inhibitory interaction 
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with the ITK kinase domain, those in yellow, ball and stick are ITK residues listed in the 
COSMIC database. F30 is shown in red with ball and stick to indicate that it both affects 
the PHTH/Kinase interface and is mutated in the database of somatic mutations in cancer. 
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CHAPTER 4 
STUDY OF THE INTERACTION OF ITK PHTH WITH ITK KINASE DOMAIN 
USING BIMOLECULAR FLUORESCENCE COMPLEMENTATION ASSAY 
 
 
 
Abstract 
Interleukin-2 inducible T cell kinase (ITK) functions in immune response 
mediated by T cells, and is a attractive drug target for autoimmune diseases and allergies. 
Regulatory intramolecular interaction surface of ITK could serve as small molecules 
target. Our studies have found that the ITK PHTH/Kinase domain intramolecular 
interaction keeps ITK in the autoinhibited state. Two sets of mutations in the ITK PHTH 
domain, K48D/R49D and V28E/F30Y, disrupt this autoinhibitory interaction hence 
increasing the catalytic activity of ITK. Hence, this interaction interface is a plausible 
allosteric target for small molecules that regulate kinase activity. With the ultimate goal 
of developing a high-throughput assay to target ITK PHTH/Kinase interaction site, we 
developed the cell based bimolecular fluorescence complementation (BiFC) assay. In the 
BiFC assay, the ITK Kinase domain was fused to the non-fluorescent N-terminal 
fragment of YFP variant Venus while the ITK PHTH domain-containing construct was 
fused to the non-fluorescent C-terminal fragment of Venus. The ITK PHTH/Kinase 
interaction allows for the two N- and C-terminal fragments of Venus to structurally 
complement forming functional fluorophore and BiFC to occur hence, giving rise to 
fluorescence. The BiFC signal was detected on wildtype ITK PHTH/kinase pair but in the 
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case of the PHTH domain mutant (K48D/R49D), which disrupts the ITK PHTH/kinase 
interaction, BiFC signal was reduced. This study lays the groundwork for a highthrough 
put assay for small molecule screening that modulates the ITK PHTH/Kinase interaction  
 
Introduction 
 Interleukin-2 inducible T cell kinase (ITK) is non-receptor tyrosine kinase 
primarily expressed in T cells, which plays a crucial role in propagating signals 
downstream of the T cell receptor (TCR). Upon TCR engagement, ITK is responsible for 
phosphorylation of Phospholipase C γ1 (PLCγ1), leading to PLCγ1 activation. Activated 
PLCγ1 then catalyzes the hydrolysis of phosphatidylinositol-(4,5)-bisphosphate (PIP2) in 
the membrane to inositol (1,4,5)-triphosphate (IP3) and diacylglyecrol (DAG). IP3 and 
DAG mediate signaling that eventually lead to expression of various cytokines that are 
responsible for appropriate immune responses.  ITK is a key modulator of T cell 
responses, and is therefore an attractive target for small molecule intervention that tunes 
ITK activity.  
  
 ITK has been linked to various diseases. Loss of function mutations in ITK leads 
to fatal Epstein-Barr virus induced lymphoproliferative diseases (EBV-LPD) (1). Also, 
ITK has been linked to a hyperactive immune response in asthma and autoimmune 
diseases. ITK deficient mice have been shown to be resistant to ovalbumin induced 
asthma (2). In addition, autoimmune diseases like multiple sclerosis and inflammatory 
bowel diseases are linked to ITK (3). Hence, this has generated significant interest in ITK 
as therapeutic target against EBV-LPD, asthma and various autoimmune diseases. Small 
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molecules, that break autoinhibition of ITK could treat EBV-LPD and small molecules 
that stabilize the ITK PH/Kinase interaction could treat hyperactive immune response 
like asthma and autoimmune diseases.  
 
There has been significant effort in targeting the ITK active site for competitive 
ATP binders (4, 5). However, all kinases share similar structural features in their active 
site hence, developing the small molecule binders that do not cross-react with other 
kinases can be very challenging (6). One to overcome this challenge is to look for and 
target allosteric regulatory sites specific to ITK. Along with the active site, ITK can also 
be targeted at various binding interfaces between its domains, since the non-catalytic 
PHTH, SH3 and SH2 domains regulate ITK kinase activity by directly interacting with 
the kinase domain. In chapter 3, we have characterized the specific autoinhibitory 
interaction between the ITK PHTH domain and ITK kinase domain and we have shown 
that K48D/R49D and V28E/F30Y mutations in the PHTH domain disrupt this interaction 
making ITK more catalytically active. Hence the ITK PHTH/kinase domain interaction 
surface could be very plausible target for small molecule intervention. Small molecules 
that could influence the kinase activity of ITK by modulating ITK PH/kinase domain 
interaction will be useful in treating various disease conditions. 
  
A cell based bimolecular fluorescence complementation (BiFC) assay has been 
used previously in a high-throughput format to screen small molecules that target protein-
protein interactions (7). In the BiFC assay, two interacting proteins are fused to 
complementary non-fluorescent N-terminal and C-terminal fragments of the Green 
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fluorescent protein (GFP) or yellow fluorescent protein (YFP)(8, 9). When two 
interacting proteins are co expressed in cells, their interaction brings the complementary 
non-fluorescent fragments of GFP or YFP together allowing for structural 
complementation to occur and the formation of the functional fluorophore (9). Hence, 
protein interactions inside cells can be visualized directly using a fluorescence 
microscope. Here, we set out to test whether the BiFC assay is suited to detect the 
interaction between the ITK PHTH domain and kinase domain and whether this 
technique can be adapted to high throughput screening of the small molecules targeting 
the ITK PH/kinase interaction. Our preliminary result suggests that ITK kinase domain 
and ITK PHTH domain interact in cells giving rise to BiFC signal. Furthermore, the 
BiFC signal is diminished when the ITK PHTH mutant (K48D/R49D), which disrupts 
kinase domain binding, is co expressed with ITK kinase domain. These data indicate that 
the BiFC complex forms only when the ITK kinase domain interacts with the ITK PHTH 
domain.  
 
Results and Discussion 
 In chapter 3, we provided evidence for a specific interaction between the ITK 
kinase domain and ITK PH domain in vitro using NMR titration and pull down assays. 
To probe whether this interaction occurs in cells, we developed a BiFC assay specific to 
the ITK domains of interest. For the BiFC experiments, separate expression vectors 
containing the ITK PHTH-SH3 construct fused with the C-terminus (VC 154-238) of 
Venus (YFP variant) and the ITK Kinase domain fused with the N-terminus (VN 1-154) 
of Venus were created. The constructs used in our BiFC assay are shown in Figure 1.  
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Figure 1. Fusion constructs of the ITK PHTH domain containing construct with Venus C 
terminal fragment (VC) and three fusion constructs of the ITK kinase domain with Venus 
N terminal fragment (VN). The three kinase domain constructs are untagged, N terminal 
myc tagged and C terminal myc tagged.  
  
  
When co expressed in HEK 293T cells, the ITK kinase domain/PHTH domain 
interaction should bring two non-florescent Venus fragments in close proximity, resulting 
in structural complementation of the two non-fluorescent fragments of Venus leading to 
the fluorescent signal as shown in Figure 2.  
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Figure 2. Principle of BiFC. Non fluorescent fragments of YFP variant Venus denoted       
by VN and VC are fused to the ITK kinase domain and ITK PHTH-SH3 respectively. 
Co-expression and interaction between two proteins also brings VN and VC together 
giving rise to the green fluorescence signal.  
  
We monitored and compared three different ITK kinase domain constructs shown 
in Figure 1, for their ability to give BiFC signal when co-transfected with ITK PHTH 
containing construct (Figure 3). All three construct tested gave rise to comparable BiFC 
signal for 72 hours post transfection. For all three fusion construct tested, the BiFC signal 
increased from 24 hours post transfection to 48 hours post transfection. However, no 
significant increase in BiFC was observed, from 48 hours to 72 hours post transfection as 
shown in Figure 3.   
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Figure 3. BiFC images captured using fluorescence microscope. BiFC constructs 
containing untagged, N terminal myc tagged and C terminal myc tagged ITK kinase 
domain fused to VN and ITK PHTH-SH3 fused to VC were co-transfected and monitored 
for BiFC signal post 24, 48 and 72 hours after transfection.  
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To confirm that BiFC signal is dependent on the interaction between ITK kinase 
domain and ITK PH domain, the assay was repeated with the ITK PH mutant where 
arginine 48 and lysine 49 were mutated to aspartic acid. This construct is denoted as 
K48D/R49D. This ITK PH domain mutant is shown to be incapable of binding ITK 
kinase domain in our previous in vitro pull down studies. Co-expression of the ITK PH 
mutant with ITK kinase domain shows reduction in the BiFC signal intensity compared 
to wildtype as shown in Figure 4, which is consistent with our previous in vitro results.  
 
Figure 4. BiFC images comparing fluorescence signal for wildtype and interaction 
deficient mutant (K48D/R49D) mutant of ITK PH domain (left). Brightfield images show 
similar cell density in both BiFC image areas.  (right). 
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However, for this experiment total ITK PHTH and its mutant needs to be 
determined since the reduction in BiFC in mutant protein could also be due to lower 
expression level than wildtype protein. This experiment will be repeated and total protein 
expression level of all proteins will also probed along with BiFC. Total protein 
expression level will be probed by immunofluorescence microscopy. ITK kinase domain 
will be probed by anti myc antibodies while PHTH domain will be probed with anti ITK 
antibodies. After further confirmation that the BiFC signal is dependent upon 
ITKPHTH/kinase domain interaction, this assay will be adapted in high throughput 
format. In addition, by simultaneously monitoring the BiFC signal and total protein 
expression level, in the presence of small molecules, we will be able to screen small 
molecules that modulate ITK PHTH/kinase domain interaction. Wildtype PHTH 
constructs was used in this study, However, previous studies in our lab suggest that ITK 
PHTH domain is very unstable in vitro and two mutations C96E/T110I increases the 
stability of the protein (10). The BiFC assay with this solubilizing mutant will also be 
tested in future.   
 
Materials and Methods 
BiFC expression vectors 
 Mammalian expression vector pcDNA3.1(-) with Nef VN and ITK PHTHSH3-
VC was kindly provided by Dr. Tom Smithgall laboratory at University of Pittsburgh. 
ITK kinase domain was cloned into the pcDNA3.1(-) Nef VN vector using EcorI and 
HindIII restriction sites.  
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Cell culture 
 Human HEK 293T cells purchased from ATCC were thawed at 370 C water bath 
and transferred to centrifuge tube containing 9 ml of complete media. Complete media 
consist of Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum (Gibco). The cells were spun at 125 x g for 10 minutes and the cell pellet 
was resuspended in 5ml complete DMEM media pre-equilibrated in incubator with 5% 
CO2 for 15 minutes to allow the media to reach its normal pH (7-7.6). The culture was 
transferred to 25 cm2 culture flask (Corning) and incubated at 370C incubator with 5% 
CO2 in air atmosphere. After 2 days, the cells were subcultured to 75 cm2 flask (corning). 
The culture medium was removed and the cells were washed briefly with PBS buffer to 
remove traces of trypsin inhibitors from the medium. After that, 0.6 ml of Trypsin-EDTA 
solution was added to the cells to disperse the cell layer. After 5 minutes, 5 ml of 
complete growth medium was added to the flask and cells were aspirated gently by 
pipetting. The cells were transferred to the 75cm2 flask with 13 ml complete growth 
medium. After that, the cells were subcultured in 1:3 ratio every 3 days.  
 
BiFC assay and fluorescence microscopy 
 In each 35mm dish, 8X105 cells were plated and were incubated for 24 hours. 
Next day, transfection mixture consisting of X-tremeGENE 9 DNA Transfection reagent 
(Roche) and plasmid DNA was prepared for transfection. Firstly, X-tremeGENE 9 DNA 
was diluted with serum free DMEM medium to a concentration of 3ml reagent/100 ml 
medium for 3:1. 1µg of plasmid DNA was added to 100ml of diluted X-tremeGENE 
DNA reagent and incubated in room temperature for 15 minutes. The 35 mm dishes were 
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removed from the incubator and transfection mixture was added to the cells in drop wise 
manner. BiFC was monitored for 3 days post transfection, using fluorescence microscope 
(Zeiss.) from Iowa State hybridoma facilities. 
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CHAPTER 5  
GENERAL CONCLUSIONS 
 
 
Summary 
Interleukin-2 inducible tyrosine kinase (ITK) is a member of Tec family kinase 
that is expressed in T cells and is a key mediator of T cell signaling pathway. In this 
pathway, ITK is activated by phosphorylation by SRC family kinase LCK (1). Activated 
ITK then mediates activation of the Phospholipase Cγ1 (PLCγ1) by phosphorylating at 
tyrosine 783. This phosphorylation activates the PLCγ1 and its lipase activity. PLCγ1 
hydrolyses phosphatidylinositol (4,5)-bisphosphate (PIP2) to produce second messengers 
inositol-(3,4,5)-triphosphate (IP3) and diacylglycerol (DAG). ITK has been linked with 
various disease states ranging from immunodeficiency, autoimmune diseases and 
allergies (2-4). Hence, ITK has been putative drug target to treat these human maladies. 
To target ITK for small molecules, understanding of its regulation mechanism is 
important. Hence, the main goal of this thesis is to understand the underlying regulatory 
mechanism of ITK that influences the phosphorylation of its PLCγ1 substrate.  
 
Phosphorylation target for the ITK in PLCγ1 is tyrosine 783 which is located 
within 33 amino acid long linker between PLCγ1 C terminal Src homology 2 (SH2C) 
domain and Src homology 3 (SH3) domain. Crystal structure of the PLCγ1 SH2N-SH2C-
linker shows, the intramolecular interaction between the PLCγ1 SH2C and linker (5). 
This PLCγ1 conformation makes Y783 inaccessible to ITK for phosphorylation and 
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keeps PLCγ1 in autoinhibited state. This autoinhibitory interaction needs to be disrupted 
to make Y783 in the linker accessible to ITK.  
 
In chapter 2, I investigated the mechanism that disrupts this autoinhibitory 
conformation of the PLCγ1. Our result elucidates the role of scaffold protein SLP-76 to 
disrupt the PLCγ1 autoinhibition. SLP-76 phosphotyrosine 173 (pY173) interacts with 
SH2C domain of PLCγ1. NMR titration and fluorescence titration studies suggest that 
peptide containing SLP-76 pY173 interacts with PLCγ1 SH2C with higher affinity than 
SH2C-linker construct suggesting SLP-76 pY173 and the linker compete with SH2C 
binding. SLP-76 pY173 interaction with SH2C ultimately makes PLCγ1 a better substrate 
for the ITK. ITK mediated phosphorylation of PLCγ1 783 was increased with the 
addition of SLP-76 pY173 peptide in kinase assay mixture. We describe this role of SLP-
76 as substrate priming as it primes PLCγ1 the substrate ITK for phosphorylation. 
Together, our study provides the understanding on disruption of autoinhibitory 
conformation of the PLCγ1 and recognizes the new role of the scaffold SLP-76, along 
with co-localizing enzyme and substrate.  
 
In chapter 3, I study the autoregulatory intramolecular interaction within ITK. 
ITK consist of four domains PHTH, SH3, SH2 and Kinase domain. PHTH, SH3 and SH2 
domains are regulatory domains of ITK as they regulate the catalytic activity of the ITK. 
However, due to the lack of the full length structure of the ITK, precise mechanism on 
how these non-catalytic domain regulate kinase activity is not fully understood. This 
dissertation studies the role of PHTH domain on regulating kinase activity. Previous 
 117 
studies in our lab has have shown that kcat for ITK lacking PHTH domain, is fivefold 
higher than the full length ITK (6).  
 
In this thesis, I have expanded our understanding on this observation and 
characterized the regulatory role of PHTH domain in detail. Our studies shows that ITK 
PHTH domain and ITK kinase domain interact intramolecularly and this interaction 
keeps ITK in an auto inhibited state. First of all, pull down assay shows ITK PHTH 
domain interacts with ITK kinase domain in trans. To map the ITK interacting surface on 
the ITK PH domain, NMR titration experiment was carried out where ITK kinase domain 
was titrated into 15N labeled ITK PHTH domain. Using the 1H-15N NMR assignment of 
the ITK PHTH domain, I was able to map the ITK interaction surface on ITK PHTH 
domain. NMR titration experiment detects changes on the resonance of the PHTH 
residues when ITK PHTH/kinase complex is formed. Refining of the binding interface 
was done by mutagenesis and pull down studies. Using this method, I was able to identify 
two sets of residues (K48/R49 and V28/F30) in ITK PHTH domain, when mutated 
resulted in abrogation of ITK kinase domain binding. These, sets of residues, when 
mutated in the context of the full length ITK led to increase in the activity of the ITK.  
 
The ITK kinase domain-binding interface in PHTH domain is adjacent to 
phosphatidylinositol (3,4,5)-triphosphate (PI (3,4,5) P3) binding pocket of the PHTH 
domain. Inositiol (1,3,4,5)-trisphosphate (IP (1,3,4,5) P4), the soluble head group of the 
of PI (3,4,5) P3, competes with the ITK kinase domain for binding ITK PHTH domain. 
Also, liposome containing PI (3,4,5) P3 increases the catalytic activity of the ITK. Hence, 
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PI (3,4,5) P3 binding of PHTH domain releases its interaction with kinase domain leading 
to the activation of the enzyme. ITK PHTH domain interaction with PI (3,4,5) P3 also 
exposes the activation loop Y511 of full length ITK making this residue more accessible 
to LCK for phosphorylation. This study, have significantly expanded our understanding 
PHTH domain mediated regulation of the ITK activity. An ITK PHTH/Kinase regulatory 
interaction site has been identified and can be targeted for small molecule to modulate 
kinase activity.  
 
In an effort to develop the cell-based assay to monitor ITK PHTH/Kinase 
interaction, and ultimately to use this assay to screen small molecules, bimolecular 
complementary fluorescence (BiFC) assay was developed (Chapter 4). Two 
complementary non-fluorescent fragment of Venus (yellow fluorescent protein variant) 
when fused to ITK PHTH domain and ITK kinase domain and co expressed in cells, gave 
rise to fluorescence signal. ITK PHTH/Kinase interaction brings two non-fluorescent 
fragments of Venus closer and allowing for the structural complementation to occur, and 
forming functional fluorophore, giving rise to fluorescence. This assay will be further 
developed and adapted to high throughput format so that it can be used to screen for 
small molecules that modulate ITK PHTH/Kinase interaction. 
 
 This thesis, characterized the ITK kinase domain binding surface in ITK PHTH 
domain however, the complementary surface on ITK kinase domain is not known. So, 
further investigation must be carried out to identify the ITK PHTH binding surface on 
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ITK kinase domain. Co-crystallization of ITK PHTH and kinase domain will shed light 
into this interaction. Other way to characterize the binding surface is by mutagenesis and  
pull down experiments. Here, panel of mutant ITK kinase domain could be screened for 
their ability to disrupt its interaction with ITK PH domain using pull down assay. 
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